<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Sci Rep</journal-id><journal-id journal-id-type="iso-abbrev">Sci Rep</journal-id><journal-id journal-id-type="pmc-domain-id">1579</journal-id><journal-id journal-id-type="pmc-domain">scirep</journal-id><journal-title-group><journal-title>Scientific Reports</journal-title></journal-title-group><issn pub-type="epub">2045-2322</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12098671</article-id><article-id pub-id-type="pmcid-ver">PMC12098671.1</article-id><article-id pub-id-type="pmcaid">12098671</article-id><article-id pub-id-type="pmcaiid">12098671</article-id><article-id pub-id-type="pmid">40404853</article-id><article-id pub-id-type="doi">10.1038/s41598-025-99718-x</article-id><article-id pub-id-type="publisher-id">99718</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Ecofriendly first-derivative synchronous fluorometric method for simultaneous determination of atorvastatin and aspirin in pharmaceutical preparations</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Abuseada</surname><given-names initials="HHM">Hamed H. M.</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Abdel Sattar</surname><given-names initials="OI">Osama I.</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Madkour</surname><given-names initials="AW">Ahmed W.</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Taha</surname><given-names initials="AS">Ahmed S.</given-names></name><address><email>ahmedsobhytaha@gmail.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05fnp1145</institution-id><institution-id institution-id-type="GRID">grid.411303.4</institution-id><institution-id institution-id-type="ISNI">0000 0001 2155 6022</institution-id><institution>Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, </institution><institution>Al-Azhar University, </institution></institution-wrap>Cairo, 11751 Egypt </aff></contrib-group><pub-date pub-type="epub"><day>22</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>15</volume><issue-id pub-id-type="pmc-issue-id">478255</issue-id><elocation-id>17787</elocation-id><history><date date-type="received"><day>31</day><month>12</month><year>2024</year></date><date date-type="accepted"><day>22</day><month>4</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>22</day><month>05</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>23</day><month>05</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-05-24 00:25:15.767"><day>24</day><month>05</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="41598_2025_Article_99718.pdf"/><abstract id="Abs1"><p id="Par1">The combination of atorvastatin (ATO) and aspirin (ASP) is widely prescribed for preventing cardiovascular diseases, particularly in individuals at risk of atherosclerosis and myocardial infarction. This study aims to develop and validate an eco-friendly spectrofluorimetric method using the first-derivative synchronous fluorescence (FDSSF) technique (&#916;&#955;&#8201;=&#8201;80 nm) to simultaneously determine ATO and ASP in combined pharmaceutical formulations. A simple, rapid, cost-effective, and interference-free FDSSF method was employed. Ethanol was used as a green solvent, with a scanning rate of 500 nm/min and &#916;&#955; of 80 nm. Distinct fluorescence peaks for ATO and ASP were observed at 384 nm and 365 nm, respectively. The method was optimized for parameters influencing fluorescence intensity, ensuring enhanced sensitivity and selectivity. The method demonstrated excellent linearity (0.4&#8211;6 &#956;g/ml for ATO, 1&#8211;10 &#956;g/ml for ASP) with high sensitivity, as indicated by low LOD (0.03 &#956;g/ml for ATO, 0.342 &#956;g/ml for ASP) and LOQ (0.248 &#956;g/ml for ATO, 0.714 &#956;g/ml for ASP). The method was successfully applied to commercial tablet formulations and synthetic mixtures, yielding results comparable to HPLC, confirming its high accuracy and reproducibility. Environmental Assessment: The method was evaluated for &#8220;greenness&#8221; (AGREE, Complex MOGAPI, NEMI), &#8220;whiteness&#8221; (RGB12), and &#8220;blueness&#8221; (BAGI), achieving high sustainability scores. The results confirmed its minimal environmental impact and eco-friendly nature. The FDSSF method provides a green, accurate, and reliable approach for simultaneously determining ATO and ASP in pharmaceuticals, offering high sensitivity, exceptional selectivity, and environmental sustainability.</p><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1038/s41598-025-99718-x.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Atorvastatin</kwd><kwd>Aspirin</kwd><kwd>Fluorimetry analysis</kwd><kwd>First derivative synchronous</kwd><kwd> Eco-friendly analysis</kwd></kwd-group><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Chemistry</kwd><kwd>Physics</kwd></kwd-group><funding-group><award-group><funding-source><institution>Al-Azhar University</institution></funding-source></award-group><open-access><p>Open access funding provided by The Science, Technology &amp; Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB).</p></open-access></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer Nature Limited 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par2">The quality and effectiveness of pharmaceutical formulations depend on precise and reliable analytical techniques. Ensuring drug safety and regulatory compliance requires robust methods for accurately quantifying active pharmaceutical ingredients (APIs) and detecting impurities that could compromise drug stability and patient health. Simultaneously quantifying multiple APIs remains a significant challenge, particularly in drug combinations like atorvastatin (ATO) (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>a) and aspirin (ASP) (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>b), which are widely used for cardiovascular disease prevention<sup><xref ref-type="bibr" rid="CR1">1</xref>,<xref ref-type="bibr" rid="CR2">2</xref></sup>.</p><p>
<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Shows the structural formulas for ATO (<bold>1a</bold>) and ASP (<bold>1b</bold>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e200" position="float" orientation="portrait" xlink:href="41598_2025_99718_Fig1_HTML.jpg"/></fig>
</p><p id="Par3">Pharmaceutical analysis plays a crucial role in impurity profiling, which is essential for detecting trace levels of degradation products and contaminants. Traditional methods such as high-performance liquid chromatography (HPLC), spectrofluorimetry, spectroscopy, and capillary electrophoresis are commonly employed for impurity quantification. Integrating impurity profiling into analytical method development strengthens drug quality assessment and ensures adherence to regulatory standards. Recent advancements underscore the need for more sensitive and selective techniques to enhance drug purity and efficacy<sup><xref ref-type="bibr" rid="CR3">3</xref>&#8211;<xref ref-type="bibr" rid="CR7">7</xref></sup>.</p><p id="Par4">This study aims to develop an accurate and efficient first-derivative synchronous fluorescence spectrofluorimetric (FDSFS) method for simultaneously determining ATO and ASP in bulk powders and pharmaceutical formulations.</p><p id="Par5">Synchronous fluorescence spectroscopy (SFS) offers several advantages over conventional fluorescence techniques, including spectral band narrowing, simplified emission spectra, and enhanced selectivity<sup><xref ref-type="bibr" rid="CR8">8</xref></sup>. These features make SFS highly effective for analyzing multi-component mixtures without requiring pre-separation steps. Combining SFS with derivative techniques further improves sensitivity and selectivity by reducing spectral overlap, a common limitation of traditional fluorescence methods. These advantages make it a promising approach for monitoring drug quality through trustworthy analytical techniques to ensure patient safety<sup><xref ref-type="bibr" rid="CR9">9</xref>&#8211;<xref ref-type="bibr" rid="CR13">13</xref></sup>. SFS and its derivatives have recently been utilized for identifying drug combinations in biological fluids and dosage forms<sup><xref ref-type="bibr" rid="CR14">14</xref>&#8211;<xref ref-type="bibr" rid="CR22">22</xref></sup>.</p><p id="Par6">Despite the therapeutic significance of ATO-ASP combinations, most reported analytical techniques rely on HPLC, electrochemical, and spectrophotometric methods<sup><xref ref-type="bibr" rid="CR23">23</xref>&#8211;<xref ref-type="bibr" rid="CR26">26</xref></sup>. Conventional and synchronous spectrofluorimetric methods have yet to be utilized for analyzing the binary mixture of ASP and ATO in biological fluids or pharmaceutical dosage forms due to significant fluorescence spectral overlap. This limitation makes conventional fluorometric methods unsuitable for precise estimation. However, FDSFS effectively overcomes this obstacle by utilizing derivative amplitude measurements, which provide additional advantages in selectivity and sensitivity.</p><p id="Par7">Fluorometric techniques offer significant advantages over simpler and cost-effective methods, such as spectrophotometry and electrochemical analysis. Unlike HPLC, which requires extensive sample preparation and costly solvents, spectrofluorimetric methods enable rapid analysis with minimal sample handling. Additionally, they achieve lower detection limits and higher specificity in complex pharmaceutical matrices, making them invaluable for routine quality control<sup><xref ref-type="bibr" rid="CR27">27</xref>&#8211;<xref ref-type="bibr" rid="CR33">33</xref></sup>.</p><p id="Par8">As sustainability becomes a growing priority, analytical method development must align with the principles of Green Analytical Chemistry (GAC) to minimize environmental impact. GAC emphasizes reducing hazardous chemicals, limiting waste production, and optimizing energy efficiency throughout method development. The FDSFS method exemplifies this approach by significantly minimizing the use of hazardous solvents and reducing energy consumption, making it an environmentally friendly alternative to conventional techniques. To ensure its sustainability, standardized greenness assessment tools, including the Analytical Greenness Metric (AGREE), the Complex Multi-Objective Green Analytical Procedure Index (Complex MOGAPI), and the National Environmental Methods Index (NEMI), have been applied. These tools evaluate solvent selection, waste reduction, and energy efficiency, providing a comprehensive assessment of the method&#8217;s green profile. By integrating GAC principles and utilizing well-established assessment tools, the FDSFS method achieves a balance between analytical efficiency and environmental responsibility, paving the way for more sustainable practices in pharmaceutical and chemical analysis<sup><xref ref-type="bibr" rid="CR34">34</xref>&#8211;<xref ref-type="bibr" rid="CR41">41</xref></sup>.</p><p id="Par9">A common challenge in pharmaceutical analysis is interference from excipients, essential components of drug formulations. Binders, fillers, and lubricants can affect fluorescence signals, potentially compromising sensitivity and specificity. However, the FDSFS method is meticulously optimized to eliminate any excipient interference. Through advanced spectral correction, precise solvent selection, and method refinement, it ensures fluorescence signals remain accurate and unaffected. By effectively addressing excipient interactions, this method guarantees reliable, interference-free drug quantification under all conditions<sup><xref ref-type="bibr" rid="CR42">42</xref></sup>.</p><p id="Par10">For any analytical technique to be widely adopted, it must demonstrate feasibility in real-world pharmaceutical applications. The FDSFS method has proven to be highly accurate and robust in laboratory studies. This refined technique ensures precise and dependable results while offering substantial practical benefits for the simultaneous analysis of ATO and ASP in combined pharmaceutical formulations. They present a cost-efficient, environmentally friendly, and sustainable solution for routine quality control in the pharmaceutical industry. With their straightforward implementation, minimal solvent usage, and operational efficiency, these methods are particularly well-suited for large-scale ATO and ASP formulation analysis. By enabling precise quantification while reducing environmental impact, they support regulatory compliance and advance sustainability in pharmaceutical testing<sup><xref ref-type="bibr" rid="CR43">43</xref>&#8211;<xref ref-type="bibr" rid="CR46">46</xref></sup>.</p><p id="Par11">Emerging technologies are driving the evolution of pharmaceutical analysis. Miniaturized fluorescence sensors, quantum dot-based detection systems, and advanced spectroscopic techniques are gaining traction for drug quantification due to their superior automation, high throughput, and exceptional sensitivity. Integrating SFS with these cutting-edge innovations will further enhance its precision and applicability in pharmaceutical quality control, ensuring that modern analytical methods remain competitive and highly effective<sup><xref ref-type="bibr" rid="CR6">6</xref>,<xref ref-type="bibr" rid="CR47">47</xref>&#8211;<xref ref-type="bibr" rid="CR51">51</xref></sup>.</p><p id="Par12">By addressing key challenges in drug analysis, the proposed FDSFS method provides a selective, sensitive, and environmentally sustainable approach for the simultaneous determination of ATO and ASP. Its successful application in tablet formulations highlights its potential as a reliable tool for routine pharmaceutical quality monitoring, ensuring drug safety and efficacy.</p></sec><sec id="Sec2"><title>Experimental</title><sec id="Sec3"><title>Materials</title><sec id="Sec4"><title>Pure samples</title><p id="Par13">Pure ATO (99.73%) was supplied by Lipits Pharmaceuticals, 6th of October City, Egypt. Its purity was verified using the proposed method<sup><xref ref-type="bibr" rid="CR52">52</xref></sup>.</p><p id="Par14">Pure ASP (99.69%) was obtained from GlaxoSmithKline Pharmaceutical Industries, Cairo, Egypt, and its purity was verified using the established method<sup><xref ref-type="bibr" rid="CR53">53</xref></sup>.</p></sec><sec id="Sec5"><title>Pharmaceutical preparation</title><p id="Par15">Atorlip Asp-20 tablets, manufactured by Cipla Ltd., India, were labeled to contain 20 mg of ATO and 75 mg of ASP. The tablets were procured from a local market in India.</p></sec><sec id="Sec6"><title>Chemicals and reagents</title><p id="Par16">The water used in the process was freshly distilled, and all reagents and solvents were of analytical grade.<list list-type="bullet"><list-item><p id="Par17">Organic solvents: Analytical-grade 1-propanol, ethanol (98.8%), acetonitrile, methanol, tetrahydrofuran, and chloroform were obtained from Sigma-Aldrich (Germany).</p></list-item><list-item><p id="Par18">Chemical reagents: Glacial acetic acid, boric acid, sodium hydroxide, sodium acetate, monobasic potassium phosphate, potassium chloride, Methylcellulose (MC, 0.5% aqueous solution), Tween 80 (0.5% aqueous solution), sodium dodecyl sulfate (SDS, 0.5% aqueous solution) and potassium bi-phthalate were supplied by El-Nasr Company (Egypt).</p></list-item><list-item><p id="Par19">Buffer solutions: Prepared according to the US Pharmacopeia guidelines:</p></list-item><list-item><p id="Par20">pH 2 buffer: Potassium chloride and hydrochloric acid.</p></list-item><list-item><p id="Par21">pH 3 buffer: Acid phthalate buffer.</p></list-item><list-item><p id="Par22">pH 4&#8211;5 buffer: Acetate buffer.</p></list-item><list-item><p id="Par23">pH 6&#8211;7 buffer: Phosphate buffer.</p></list-item><list-item><p id="Par24">pH 9&#8211;10 buffer: Alkaline borate buffer.</p></list-item></list></p></sec><sec id="Sec7"><title>Apparatus</title><p id="Par25">
<list list-type="bullet"><list-item><p id="Par26">All measurements were carried out using the Jasco FP-6200 Spectrofluorometer (Tokyo, Japan), with spectral data processed through Jasco Spectra Manager software. The monochromator slit widths were set to 10 nm, and a 1 cm quartz cell was used. Measurements were performed at medium sensitivity.</p></list-item><list-item><p id="Par27">A Jenway 3510 pH meter (England) with a reference electrode (model 924017 LO3-Q11C) was used for Ag/AgCl measurements.</p></list-item><list-item><p id="Par28">A Precisa 125A analytical balance (Switzerland) was employed for precise weighing.</p></list-item></list>
</p></sec><sec id="Sec8"><title>Standard and working solutions</title><p id="Par29">Stock standard solutions of ATO (1000 &#956;g/mL) and ASP (1000 &#956;g/mL) were prepared by dissolving 100 mg of each drug in 50 mL of ethanol (98.8%) in separate 100 mL volumetric flasks. The solutions were then diluted to the mark with the same solvent. To obtain the working solutions, 2.5 mL of each stock solution was transferred into a 100 mL volumetric flask and further diluted with ethanol to the final volume, yielding ATO and ASP concentrations of 25 &#956;g/mL.</p></sec></sec></sec><sec id="Sec9"><title>Procedures</title><sec id="Sec10"><title>Creating calibration graphs</title><p id="Par30">Aliquots of the working standard ATO and ASP solutions (25 &#181;g/mL) were transferred into 10-mL volumetric flasks. After adding 1 mL of 0.2 M acetate buffer (pH 5), the solutions were diluted to the 10 mL mark with ethanol and thoroughly mixed to ensure homogeneity. Synchronous fluorescence spectra were recorded by scanning both monochromators at a constant &#916;&#955; of 80 nm. The first derivative of each synchronous spectrum was obtained using a data interval of 15 points at 384 nm and 365 nm for ATO and ASP, respectively, and the corresponding peak amplitudes were measured. A blank experiment was conducted in parallel. Calibration curves for each drug were constructed by plotting the first derivative (1D) amplitude against the final concentration in &#181;g/mL, followed by the derivation of the corresponding regression equations and calibration graphs.</p></sec><sec id="Sec11"><title>Procedure for laboratory-prepared mixtures</title><p id="Par31">The selectivity of the proposed method for ATO in the presence of ASP was assessed by analyzing laboratory-prepared mixtures containing ATO and ASP in various ratios. Five distinct 10-mL volumetric flasks were prepared, each representing a different mixture ratio (1:3.75). For each mixture, appropriate volumes of ATO and ASP working solutions (25 &#956;g/mL each) were transferred to achieve the desired concentrations and then diluted to the mark with ethanol. The procedure outlined under linearity and calibration graph preparation was followed. The concentrations of ATO and ASP in each mixture were determined using their respective calibration curves, and the percentage recovery (%R) was calculated to assess the method&#8217;s accuracy and selectivity.</p></sec><sec id="Sec12"><title>Pharmaceutical application</title><p id="Par32">Ten Atorlip Asp tablets, each containing 20&#160;mg of ATO and 75&#160;mg of ASP, were accurately weighed and finely ground into powder. A portion equivalent to one tablet was transferred to a 100&#160;mL volumetric flask containing 40&#160;mL of ethanol. The mixture was subjected to vigorous shaking for 20&#160;min, then filtered, and the volume was adjusted to 100&#160;mL with ethanol. The resulting solution was further diluted with ethanol to obtain five distinct concentrations. The samples were analyzed according to the specified methods for linearity and calibration curves, and the percentage recovery of each drug was determined.</p></sec><sec id="Sec13"><title>Optimization of experimental conditions</title><p id="Par33">The fluorescence intensity-affecting parameters of ATO and ASP were thoroughly examined and optimized. Some variables were individually adjusted, while others remained constant. These parameters include buffer volume, diluting solvent, pH, buffer type, and &#916;&#955;.</p></sec><sec id="Sec14"><title>Selection of optimum &#916;&#955;</title><p id="Par34">The optimal &#916;&#955; value is critical for achieving peak sensitivity, resolution, and overall performance in the synchronous fluorescence scanning (SFS) method. This parameter directly impacts both the intensity of the synchronous signal and the spectral profile. To assess its effect, a broad &#916;&#955; range (20&#8211;120&#160;nm) was examined for ATO and ASP. The results indicated that 80&#160;nm was the optimal &#916;&#955;, producing two well-defined peaks with ideal spectral shapes. In contrast, lower &#916;&#955; values led to reduced fluorescence intensity, while excessively low values caused spectral distortion for both drugs.</p></sec><sec id="Sec15"><title>The impact of surfactants</title><p id="Par35">Various surfactants were tested to determine their effect on fluorescence intensity. (Fig.&#160;<xref rid="Fig6" ref-type="fig">6</xref>a) summarizes the results for cetrimide, carboxymethylcellulose, sodium dodecyl sulfate (SDS), &#946;-cyclodextrin, and Tween 80. Compared to the initial trials without surfactants, neither ASP nor ATO exhibited a significant enhancement in fluorescence intensity with any of the tested surfactants.</p></sec><sec id="Sec16"><title>pH and buffer effect</title><p id="Par36">To assess the impact of pH on the fluorescence intensity of ASP and ATO (Fig.&#160;<xref rid="Fig6" ref-type="fig">6</xref>b), two buffer types were tested: 0.2&#160;M acetate buffer (pH 4.5&#8211;5.6) and 0.2&#160;M phosphate buffer (pH 6.0&#8211;7.0). The results revealed that ASP exhibited its highest fluorescence intensity and stability in mildly acidic conditions, with a peak at pH 5.0. However, at pH values above 5.0, spectral changes were observed, likely due to hydrolysis into salicylic acid, which can alter fluorescence properties.</p><p id="Par37">Meanwhile, ATO demonstrated moderate fluorescence and solubility in slightly acidic to near-neutral conditions. Fluorescence quenching was observed at highly alkaline pH values (pH&#8201;&gt;&#8201;9), likely due to drug degradation. Based on these findings, 0.2&#160;M acetate buffer (pH 5.0) was selected as the optimal medium, providing a balance between maximum fluorescence intensity, stability, and solubility for both ASP and ATO while minimizing hydrolysis and degradation<sup><xref ref-type="bibr" rid="CR54">54</xref>&#8211;<xref ref-type="bibr" rid="CR56">56</xref></sup>.</p></sec><sec id="Sec17"><title>Effect of diluting solvents</title><p id="Par38">When ATO and ASP were diluted in various solvents, including ethanol, acetonitrile, methanol, n-propanol, and water (Fig.&#160;<xref rid="Fig6" ref-type="fig">6</xref>c), their fluorescence intensities were maximized in ethanol. Consequently, ethanol was chosen as the optimal solvent due to its ability to provide the highest fluorescence intensity while ensuring compound stability and compatibility with the analytical method.</p><p id="Par39">Ethanol&#8217;s balanced polarity and reduced quenching effects enhance the fluorescence signals of both ATO and ASP, making it superior to other tested solvents. Additionally, ethanol stands out as the most environmentally friendly choice. Unlike acetonitrile and other organic solvents, ethanol is biodegradable, derived from renewable sources, and has a lower toxicity profile, making it safer for researchers and the environment. Its reduced environmental impact aligns with green analytical chemistry principles, promoting sustainability without compromising analytical performance. Thus, ethanol was selected as the preferred solvent for achieving maximum fluorescence intensity, chemical stability, and reproducibility while ensuring an eco-friendly approach in this study<sup><xref ref-type="bibr" rid="CR54">54</xref></sup>.</p></sec></sec><sec id="Sec18"><title>Findings and discussions</title><p id="Par40">In ethanol, Aspirin (ASP) and Atorvastatin (ATO) exhibit native fluorescence at 405 nm and 364 nm, respectively, when excited at 285 nm and 300 nm (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>). These excitation wavelengths were selected based on their intrinsic fluorescence properties, ensuring optimal excitation of each analyte to generate a strong and distinguishable emission signal. However, due to significant spectral overlap (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>), conventional fluorescence techniques lack sufficient selectivity for simultaneous determination.</p><p>
<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Shows 10 &#956;g/ml of ATO, and 20 &#956;g/ml of ASP overlapped emission fluorescence spectra.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e436" position="float" orientation="portrait" xlink:href="41598_2025_99718_Fig2_HTML.jpg"/></fig>
</p><p id="Par41">To address this limitation, synchronous fluorescence spectroscopy (SFS) was employed to enhance selectivity and facilitate the differentiation of both drugs. Figure&#160;<xref rid="Fig3" ref-type="fig">3</xref>a shows the synchronous fluorescence spectra of ATO at varying ASP concentrations, while Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>b illustrates the SFS spectra of ASP in the presence of different ATO concentrations. Despite applying SFS, considerable spectral overlap persisted, posing a challenge for independent quantification.</p><p>
<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>(<bold>a</bold>) Synchronous fluorescence spectra of ASP (8 &#956;g/ml) and ATO (1, 1.5, 2,2.5,3, 3.5,4, 4.5, and 5 &#956;g/ml). (<bold>b</bold>) Synchronous fluorescence spectra of ATO (2 &#956;g/ml) and ASP (2, 3,4, 5,6,7,8,9 and 10 &#956;g/ml).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e461" position="float" orientation="portrait" xlink:href="41598_2025_99718_Fig3_HTML.jpg"/></fig>
</p><p id="Par42">The first derivative synchronous fluorescence spectroscopy (FDSFS) was applied to enhance selectivity and eliminate spectral interference (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>a, b). Under optimized conditions (Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>), ATO was accurately determined at 384 nm, while ASP was quantified at 365 nm. The selection of &#916;&#955;&#8201;=&#8201;80 nm was systematically optimized to enhance spectral resolution and minimize peak overlap. This choice provided multiple analytical advantages, including suppression of background fluorescence, improved differentiation between ATO and ASP signals, and an enhanced signal-to-noise ratio, leading to superior fluorescence intensity and analytical precision. Furthermore, the FDSFS method eliminates the need for derivatization reagents, toxic solvents, and extensive sample preparation, making it a cost-effective, eco-friendly approach aligned with green analytical chemistry principles.</p><p>
<fig id="Fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><p>(<bold>a</bold>) First-derivative synchronous fluorescence spectra of ASP (8 &#956;g/ml) and of ATO (1, 1.5, 2,2.5,3, 3.5,4, 4.5, and 5 &#956;g/ml) at 384 nm. (<bold>b</bold>) First-derivative synchronous fluorescence spectra of: ATO (3 &#956;g/ml) and of ASP (2,3,4,5,6,7,8,9 and 10 &#956;g/ml) at 365 nm.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e486" position="float" orientation="portrait" xlink:href="41598_2025_99718_Fig4_HTML.jpg"/></fig>
</p><p>
<fig id="Fig5" position="float" orientation="portrait"><label>Fig. 5</label><caption><p>First-derivative synchronous fluorescence spectra of the prepared mixture. (<bold>a</bold>) ASP (6 &#956;g/ml); (<bold>b</bold>) ATO (2 &#956;g/ml); and (<bold>c</bold>) the mixture of 6 &#956;g/ml ASP and 2 &#956;g/ml ATO.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e506" position="float" orientation="portrait" xlink:href="41598_2025_99718_Fig5_HTML.jpg"/></fig>
</p><p id="Par43">The validated FDSFS method offers a simple, efficient, and environmentally friendly alternative to conventional chromatographic techniques for the simultaneous determination of ASP and ATO in pharmaceutical formulations. By optimizing excitation wavelengths based on intrinsic fluorescence properties and selecting an appropriate &#916;&#955;, the method ensures high selectivity and sensitivity. Additionally, it eliminates complex separation steps, making it highly suitable for routine quality control analysis in pharmaceutical industries. This technique is directly applicable to the analysis of ASP-ATO combination drugs in commercial dosage forms, ensuring compliance with regulatory standards while maintaining high accuracy, precision, and reproducibility. Its adaptability and efficiency make it a valuable tool for laboratories seeking rapid and reliable pharmaceutical analysis (Fig.&#160;<xref rid="Fig6" ref-type="fig">6</xref>).</p><p>
<fig id="Fig6" position="float" orientation="portrait"><label>Fig. 6</label><caption><p>Optimization of method conditions using ATO (2 &#181;g/mL) and ASP (6 &#181;g/mL).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e521" position="float" orientation="portrait" xlink:href="41598_2025_99718_Fig6_HTML.jpg"/></fig>
</p><sec id="Sec19"><title>Comprehensive greenness, whiteness, and blueness evaluation</title><p id="Par44">The &#8220;greenness&#8221; assessment used the NEMI Figure S1, Complex MOGAPI Figure S2, and AGREE tools. At the same time, the &#8220;blueness&#8221; and the &#8220;whiteness&#8221; were assessed using the BAGI tool and RGB12 algorithm, respectively<sup><xref ref-type="bibr" rid="CR33">33</xref>&#8211;<xref ref-type="bibr" rid="CR37">37</xref></sup>. The proposed spectrofluorimetric approach acquired high greenness, blueness, and whiteness values, as shown in Table 5.</p></sec></sec><sec id="Sec20"><title>Method validation</title><p id="Par45">According to ICH guidelines<sup><xref ref-type="bibr" rid="CR54">54</xref></sup>, the proposed method was successfully validated for accuracy, precision, selectivity, linearity, limit of detection (LOD), and limit of quantification (LOQ), ensuring its reliability and suitability for pharmaceutical analysis.</p><sec id="Sec21"><title>Linearity and range</title><p id="Par46">When the peak amplitude (1D) was plotted against drug concentration, a linear correlation was observed for ASP over 1&#8211;10&#160;&#956;g/mL at 365&#160;nm and ATO over 0.4&#8211;6&#160;&#956;g/mL at 384&#160;nm. Linear regression analysis of the data yielded the following equations:<disp-formula id="Equa"><alternatives><tex-math id="d33e546">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\begin{aligned}^{{1}} {\text{D }} = &amp; \, 0.{\text{2138C }} + { 3}.{9893 }\left( {{\text{r }} = \, 0.{9999}} \right){\text{ for ATO at 384 nm}} \\^{{1}} {\text{D }} = &amp; \, 0.{48}0{\text{6C }} - \, 0.{9123 }\left( {{\text{r }} = \, 0.{9998}} \right){\text{ for ASP at 365 nm}}, \\ \end{aligned}$$\end{document}</tex-math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="41598_2025_99718_Article_Equa.gif"/></alternatives></disp-formula>where <sup>1</sup>D represents FDSFS peak amplitude, C is the drug concentration in &#956;g/mL, and r is the correlation coefficient. This indicates that the calibration graphs are linear, as detailed in Table <xref rid="Tab1" ref-type="table">1</xref>.</p><p>
<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Regression and validation data for the suggested FDSSF procedure&#8217;s assessment of ATO and ASP.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Parameter</th><th align="left" colspan="1" rowspan="1">ATO</th><th align="left" colspan="1" rowspan="1">ASP</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Wavelength (nm)</td><td align="left" colspan="1" rowspan="1">384 nm</td><td align="left" colspan="1" rowspan="1">365 nm</td></tr><tr><td align="left" colspan="1" rowspan="1">Linearity range (&#956;g/ml)</td><td align="left" colspan="1" rowspan="1">0.4&#8211;6 &#956;g/ml</td><td align="left" colspan="1" rowspan="1">1&#8211;10 &#956;g/ml</td></tr><tr><td align="left" colspan="1" rowspan="1">Determination coefficient (r<sup>2</sup>)</td><td align="left" colspan="1" rowspan="1">0.9998</td><td align="left" colspan="1" rowspan="1">0.9999</td></tr><tr><td align="left" colspan="1" rowspan="1">Intercept</td><td align="left" colspan="1" rowspan="1">3.9893</td><td align="left" colspan="1" rowspan="1">-0.9123</td></tr><tr><td align="left" colspan="1" rowspan="1">Slope</td><td align="left" colspan="1" rowspan="1">0.2138</td><td align="left" colspan="1" rowspan="1">0.4806</td></tr><tr><td align="left" colspan="1" rowspan="1">LOD (&#956;g/mL)</td><td align="left" colspan="1" rowspan="1">0.031 &#956;g/ml</td><td align="left" colspan="1" rowspan="1">0.342 &#956;g/ml</td></tr><tr><td align="left" colspan="1" rowspan="1">LOQ (&#956;g/mL)</td><td align="left" colspan="1" rowspan="1">0.248 &#956;g/ml</td><td align="left" colspan="1" rowspan="1">0.714 &#956;g/ml</td></tr><tr><td align="left" colspan="1" rowspan="1">Accuracy (%R)<sup>a</sup></td><td align="left" colspan="1" rowspan="1">99.51</td><td align="left" colspan="1" rowspan="1">100.38</td></tr><tr><td align="left" colspan="3" rowspan="1">Precision (%RSD)<sup>b</sup></td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Repeatability</td><td align="left" colspan="1" rowspan="1">1.406</td><td align="left" colspan="1" rowspan="1">1.241</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Intermediate precision</td><td align="left" colspan="1" rowspan="1">1.117</td><td align="left" colspan="1" rowspan="1">1.051</td></tr><tr><td align="left" colspan="3" rowspan="1">Robustness<sup>c</sup> (%RSD)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#916;&#955; (&#177;&#8201;1 nm)</td><td align="left" colspan="1" rowspan="1">1.2</td><td align="left" colspan="1" rowspan="1">1.356</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;pH (&#177;&#8201;0.1)<sup>c</sup></td><td align="left" colspan="1" rowspan="1">1.02</td><td align="left" colspan="1" rowspan="1">1.089</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Phosphate buffer volume (&#177;&#8201;0.1 ml)<sup>c</sup></td><td align="left" colspan="1" rowspan="1">1.65</td><td align="left" colspan="1" rowspan="1">0.572</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>Nine determinations on average (three concentrations, three times).</p><p><sup>b</sup>The % RSD of nine measurements (three concentrations, three repetitions).</p><p><sup>c</sup>%RSD of determination of three concentrations of each drug after slight changes in the pH (&#177;&#8201;0.1) and phosphate buffer volume (&#177;&#8201;0.1 ml).</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec22"><title>Limits of detection and quantitation</title><p id="Par47">Following ICH guidelines, the LOD and LOQ were determined using the following formulas:<disp-formula id="Equb"><alternatives><tex-math id="d33e704">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\text{LOD }} = { 3}.{3 }\sigma /{\text{S}}. {\text{LOQ }} = { 1}0 \, \sigma /{\text{S}}.$$\end{document}</tex-math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="41598_2025_99718_Article_Equb.gif"/></alternatives></disp-formula>where S represents the slope of the calibration curve and &#963; is the standard deviation of the y-intercepts of the regression lines.</p><p id="Par48">The low LOD and LOQ values obtained (see Table <xref rid="Tab1" ref-type="table">1</xref>) confirm the high sensitivity of the method. Specifically, the detection limits for ASP and ATO were 0.342&#160;&#956;g/mL and 0.031&#160;&#956;g/mL, respectively. The quantification limits were 0.714&#160;&#956;g/mL for ASP and 0.248&#160;&#956;g/mL for ATO, demonstrating the method&#8217;s capability to detect and quantify the drugs at very low concentrations.</p></sec><sec id="Sec23"><title>Accuracy and precision</title><p id="Par49">To ensure the reliability of the proposed method, recovery studies were conducted at 80%, 100%, and 120% of the assay concentration, following ICH guidelines. The accepted recovery range for accuracy is typically 98.0&#8211;102.0%. Accuracy, expressed as percent recovery (%R), was evaluated for ATO at 0.8, 1, and 1.2&#160;&#956;g/mL and ASP at 1.6, 2, and 2.4&#160;&#956;g/mL. The results, in Table <xref rid="Tab1" ref-type="table">1</xref>, confirm the method&#8217;s accuracy and robustness, as all recovery values fell within the accepted range.</p><p id="Par50">For precision assessment, three concentration levels within the linearity range&#8212;ATO (1, 2, and 3&#160;&#956;g/mL) and ASP (2, 4, and 6&#160;&#956;g/mL)&#8212;were analyzed. Repeatability was evaluated through triplicate measurements on the same day (intra-day precision), while intermediate precision (inter-day precision) was assessed over three consecutive days. Precision was expressed as percent relative standard deviation (%RSD), with an accepted RSD limit of&#8201;&#8804;&#8201;2.0% as per ICH guidelines. The low %RSD values, as detailed in Table <xref rid="Tab1" ref-type="table">1</xref>, confirm the method&#8217;s high precision and reproducibility, remaining well within the accepted limit.</p></sec><sec id="Sec24"><title>Specificity and selectivity</title><p id="Par51">The proposed technique was employed to confirm the method&#8217;s specificity. The determination of ATO in ASP-prepared laboratory mixtures demonstrated excellent selectivity, as presented in Table <xref rid="Tab2" ref-type="table">2</xref>. Additionally, the standard addition method was applied to further assess specificity, with results detailed in Table <xref rid="Tab3" ref-type="table">3</xref>.</p><p>
<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>ASP and ATO assessment using the proposed technique in laboratory-prepared mixes.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Added ATO (&#956;g/mL)</th><th align="left" colspan="1" rowspan="1">ASP found (&#956;g/mL)</th><th align="left" colspan="1" rowspan="1">ATO (%R)</th><th align="left" colspan="1" rowspan="1">Added ASP (&#956;g/mL)</th><th align="left" colspan="1" rowspan="1">ASP found (&#956;g/mL)</th><th align="left" colspan="1" rowspan="1">ASP (%R)</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">0.5</td><td align="left" colspan="1" rowspan="1">0.504</td><td char="." align="char" colspan="1" rowspan="1">100.77</td><td char="." align="char" colspan="1" rowspan="1">1.875</td><td char="." align="char" colspan="1" rowspan="1">1.857</td><td char="." align="char" colspan="1" rowspan="1">99.05</td></tr><tr><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">0.981</td><td char="." align="char" colspan="1" rowspan="1">98.12</td><td char="." align="char" colspan="1" rowspan="1">3.75</td><td char="." align="char" colspan="1" rowspan="1">3.744</td><td char="." align="char" colspan="1" rowspan="1">99.83</td></tr><tr><td align="left" colspan="1" rowspan="1">1.5</td><td align="left" colspan="1" rowspan="1">1.499</td><td char="." align="char" colspan="1" rowspan="1">99.91</td><td char="." align="char" colspan="1" rowspan="1">5.625</td><td char="." align="char" colspan="1" rowspan="1">5.552</td><td char="." align="char" colspan="1" rowspan="1">98.7</td></tr><tr><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">2.027</td><td char="." align="char" colspan="1" rowspan="1">101.35</td><td char="." align="char" colspan="1" rowspan="1">7.5</td><td char="." align="char" colspan="1" rowspan="1">7.451</td><td char="." align="char" colspan="1" rowspan="1">99.34</td></tr><tr><td align="left" colspan="1" rowspan="1">2.5</td><td align="left" colspan="1" rowspan="1">2.521</td><td char="." align="char" colspan="1" rowspan="1">100.83</td><td char="." align="char" colspan="1" rowspan="1">9.375</td><td char="." align="char" colspan="1" rowspan="1">9.508</td><td char="." align="char" colspan="1" rowspan="1">101.42</td></tr><tr><td align="left" colspan="3" rowspan="1">Mean&#8201;&#177;&#8201;%RSD 100.196&#8201;&#177;&#8201;1.13612</td><td align="left" colspan="3" rowspan="1">Mean&#8201;&#177;&#8201;%RSD 99.668&#8201;&#177;&#8201;1.0632</td></tr></tbody></table></table-wrap>
</p><p>
<table-wrap id="Tab3" position="float" orientation="portrait"><label>Table 3</label><caption><p>ATO and ASP recovery investigation utilizing the proposed approach and standard addition procedure.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Drug</th><th align="left" colspan="1" rowspan="1">Pharmaceutical formulation<break/> taken (&#181;g/ml)</th><th align="left" colspan="1" rowspan="1">Pharmaceutical formulation<break/> found<sup>a</sup> (&#181;g/ml)</th><th align="left" colspan="1" rowspan="1">Pure added<break/>(&#956;g/ml)</th><th align="left" colspan="1" rowspan="1">Pure found<sup>b</sup><break/> (&#181;g/ml)</th><th align="left" colspan="1" rowspan="1">Pure recovery <break/>(%R)</th></tr></thead><tbody><tr><td align="left" rowspan="5" colspan="1">Atorvastatin</td><td align="left" rowspan="4" colspan="1">20</td><td align="left" rowspan="4" colspan="1">19.92</td><td align="left" colspan="1" rowspan="1">0.5</td><td char="." align="char" colspan="1" rowspan="1">0.496</td><td char="." align="char" colspan="1" rowspan="1">99.18</td></tr><tr><td align="left" colspan="1" rowspan="1">1</td><td char="." align="char" colspan="1" rowspan="1">0.986</td><td char="." align="char" colspan="1" rowspan="1">98.57</td></tr><tr><td align="left" colspan="1" rowspan="1">1.5</td><td char="." align="char" colspan="1" rowspan="1">1.514</td><td char="." align="char" colspan="1" rowspan="1">100.94</td></tr><tr><td align="left" colspan="1" rowspan="1">2</td><td char="." align="char" colspan="1" rowspan="1">1.974</td><td char="." align="char" colspan="1" rowspan="1">98.72</td></tr><tr><td align="left" colspan="4" rowspan="1">Mean&#8201;&#177;&#8201;%RSD</td><td align="left" colspan="1" rowspan="1">99.35&#8201;&#177;&#8201;1.097</td></tr><tr><td align="left" rowspan="5" colspan="1">Aspirin</td><td align="left" rowspan="4" colspan="1">75</td><td align="left" rowspan="4" colspan="1">75.21</td><td align="left" colspan="1" rowspan="1">1.875</td><td char="." align="char" colspan="1" rowspan="1">1.899</td><td char="." align="char" colspan="1" rowspan="1">101.28</td></tr><tr><td align="left" colspan="1" rowspan="1">3.75</td><td char="." align="char" colspan="1" rowspan="1">3.728</td><td char="." align="char" colspan="1" rowspan="1">99.4</td></tr><tr><td align="left" colspan="1" rowspan="1">5.625</td><td char="." align="char" colspan="1" rowspan="1">5.662</td><td char="." align="char" colspan="1" rowspan="1">100.65</td></tr><tr><td align="left" colspan="1" rowspan="1">7.5</td><td char="." align="char" colspan="1" rowspan="1">7.637</td><td char="." align="char" colspan="1" rowspan="1">101.83</td></tr><tr><td align="left" colspan="4" rowspan="1">Mean&#8201;&#177;&#8201;%RSD</td><td align="left" colspan="1" rowspan="1">100.79&#8201;&#177;&#8201;1.036</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>Average of five assessments.</p><p><sup>b</sup>Average of three assessments.</p></table-wrap-foot></table-wrap>
</p><p id="Par52">To evaluate the method&#8217;s applicability, ATO and ASP were quantified in Atorlip Asp tablets using the proposed approach. The results obtained through the standard addition method validated the accuracy of the analysis, showing a strong agreement with the labeled claim and confirming the absence of interference from excipients and additives.</p><p id="Par53">A statistical comparison between the results of the proposed method and those obtained using a previously reported method<sup><xref ref-type="bibr" rid="CR25">25</xref></sup> demonstrated high accuracy and precision in assessing the studied drugs in their pharmaceutical dosage form. Furthermore, applying the T-test and F-test at a 95% confidence level (5) indicated no significant differences between the two methods, as shown in Table <xref rid="Tab4" ref-type="table">4</xref>.</p><p>
<table-wrap id="Tab4" position="float" orientation="portrait"><label>Table 4</label><caption><p>Assessment of ATO and ASP in atorlip Asp tablets by the proposed approach and statistical comparison with the reported technique.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Parameters</th><th align="left" colspan="2" rowspan="1">Proposed method</th><th align="left" colspan="2" rowspan="1">Reported method<sup>a</sup><sup><xref ref-type="bibr" rid="CR12">12</xref></sup></th></tr><tr><th align="left" colspan="1" rowspan="1">ATO</th><th align="left" colspan="1" rowspan="1">ASP</th><th align="left" colspan="1" rowspan="1">ATO</th><th align="left" colspan="1" rowspan="1">ASP</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Number of measurements</td><td align="left" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">5</td></tr><tr><td align="left" colspan="1" rowspan="1">Mean % recovery</td><td align="left" colspan="1" rowspan="1">99.83</td><td align="left" colspan="1" rowspan="1">99.8</td><td align="left" colspan="1" rowspan="1">100.48</td><td align="left" colspan="1" rowspan="1">99.85</td></tr><tr><td align="left" colspan="1" rowspan="1">% RSD</td><td align="left" colspan="1" rowspan="1">1.128</td><td align="left" colspan="1" rowspan="1">0.3</td><td align="left" colspan="1" rowspan="1">1.314</td><td align="left" colspan="1" rowspan="1">0.48</td></tr><tr><td align="left" colspan="1" rowspan="1">Variance</td><td align="left" colspan="1" rowspan="1">1.269</td><td align="left" colspan="1" rowspan="1">0.09</td><td align="left" colspan="1" rowspan="1">1.743</td><td align="left" colspan="1" rowspan="1">0.23</td></tr><tr><td align="left" colspan="1" rowspan="1">Student&#8217;s <italic toggle="yes">T</italic>-test<sup>b</sup></td><td align="left" colspan="1" rowspan="1">0.828 (2.306)</td><td align="left" colspan="1" rowspan="1">1.545</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">F</italic>-value<sup>b</sup></td><td align="left" colspan="1" rowspan="1">1.373 (6.388)</td><td align="left" colspan="1" rowspan="1">2.556</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>Experiments number.</p><p><sup>b</sup>Tabulated values of "t" and "F" at (<italic toggle="yes">P</italic>&#8201;=&#8201;0.05) are shown in parenthesis.</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec25"><title>Robustness</title><p id="Par54">The robustness of the proposed method was evaluated by making minor adjustments to the optimized conditions, including slight variations in pH (&#177;&#8201;0.1) and phosphate buffer volume (&#177;&#8201;0.1 mL) while maintaining all other parameters unchanged. Each factor was altered individually to assess its impact on method performance.</p><p id="Par55">Notably, these small modifications did not significantly affect the fluorescence intensity, demonstrating the method&#8217;s reliability under slightly varied conditions. As shown in Table <xref rid="Tab1" ref-type="table">1</xref>, the percentage RSD remained below 2%, confirming the robustness of the proposed approach.</p></sec></sec><sec id="Sec26"><title>Conclusion</title><p id="Par56">In this study, we developed an eco-friendly spectrofluorimetric method for the simultaneous quantification of ASP and ATO in combined pharmaceutical formulations. The method effectively resolves overlapping signals, ensuring high sensitivity and reliability in drug analysis.</p><p id="Par57">Compared to conventional spectrophotometric and HPLC methods, this approach offers significant advantages, including enhanced sensitivity, simplicity, and the elimination of costly and complex instrumentation, making it particularly suitable for routine quality control in pharmaceutical laboratories.</p><p id="Par58">Furthermore, the developed method demonstrated excellent selectivity and efficiency, providing accurate and precise results for ASP and ATO in tablet formulations. Its successful application to Atorlip Asp tablets underscores its practical utility in ensuring the safety and efficacy of combination drug products while promoting eco-friendly and cost-effective analytical practices.</p><p id="Par59">The greenness of the proposed method was evaluated using three different assessment tools&#8212;AGREE, Complex MOGAPI, and NEMI, along with &#8220;whiteness&#8221; (RGB12) and &#8220;blueness&#8221; (BAGI), achieving high sustainability scores. These evaluations confirm that the developed method is environmentally friendly and superior to the reported HPLC method in terms of green analytical metrics, reinforcing its potential for sustainable pharmaceutical analysis, as shown in Table <xref rid="Tab5" ref-type="table">5</xref>.</p><p>
<table-wrap id="Tab5" position="float" orientation="portrait"><label>Table 5</label><caption><p>Comprehensive greenness, blueness, and whiteness evaluation of the proposed method.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="d33e1125" orientation="portrait" xlink:href="41598_2025_99718_Tab5_HTML.jpg"/></table-wrap>
</p></sec><sec id="Sec28" sec-type="supplementary-material"><title>Electronic supplementary material</title><p>Below is the link to the electronic supplementary material.</p><p>
<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41598_2025_99718_MOESM1_ESM.docx" position="float" orientation="portrait"><caption><p>Supplementary Material 1.</p></caption></media></supplementary-material>
</p></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes notes-type="author-contribution"><title>Author contributions</title><p>H.H.M.A: research idea conceptualization; supervised the study. O.I.A: Writing -review, editing, and supervision. A.W.M: data analysis; manuscript writing, revision, and editing. A.S.T: Writing &#8211; original draft, methodology, data curation, validation, and investigation. All authors read and approved of the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Open access funding provided by The Science, Technology &amp; Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB).</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.</p></notes><notes><title>Declarations</title><notes id="FPar4" notes-type="COI-statement"><title>Competing interests</title><p id="Par149">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Sweetman</surname><given-names>SC</given-names></name></person-group><source>Martindale</source><year>2009</year><publisher-loc>London, Chicago</publisher-loc><publisher-name>Pharmaceutical Press</publisher-name></element-citation><mixed-citation id="mc-CR1" publication-type="book">Sweetman, S. C. <italic toggle="yes">Martindale</italic> (Pharmaceutical Press, London, Chicago, 2009).</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Whalen</surname><given-names>K</given-names></name><name name-style="western"><surname>Finkel</surname><given-names>R</given-names></name><name name-style="western"><surname>Panavelil</surname><given-names>T</given-names></name></person-group><source>Lippincott Illustrated Reviews: Pharmacology</source><year>2015</year><edition>6</edition><publisher-loc>Gainesville (FL)</publisher-loc><publisher-name>University of Florida, College of Pharmacy</publisher-name></element-citation><mixed-citation id="mc-CR2" publication-type="book">Whalen, K., Finkel, R. &amp; Panavelil, T. <italic toggle="yes">Lippincott Illustrated Reviews: Pharmacology</italic> 6th edn. (University of Florida, College of Pharmacy, Gainesville (FL), 2015).</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rahman</surname><given-names>N</given-names></name><name name-style="western"><surname>Husain</surname><given-names>A</given-names></name><name name-style="western"><surname>Siddiqui</surname><given-names>MR</given-names></name></person-group><article-title>The importance of impurity analysis in pharmaceutical products: An integrated approach</article-title><source>Accred. Qual. Assur.</source><year>2006</year><volume>11</volume><fpage>69</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1007/s00769-006-0095-y</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Rahman, N., Husain, A. &amp; Siddiqui, M. R. The importance of impurity analysis in pharmaceutical products: An integrated approach. <italic toggle="yes">Accred. Qual. Assur.</italic><bold>11</bold>, 69&#8211;74. 10.1007/s00769-006-0095-y (2006).</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Husain</surname><given-names>A</given-names></name><name name-style="western"><surname>Haque</surname><given-names>SMJ</given-names></name><name name-style="western"><surname>Siddiqui</surname><given-names>MR</given-names></name></person-group><article-title>Identification of metabolic pathways involved in the biotransformation of eslicarbazepine acetate using UPLC-MS/MS, human microsomal enzymes and in silico studies</article-title><source>J. King Saud Univ. Sci.</source><year>2021</year><volume>33</volume><issue>2</issue><fpage>101281</fpage><pub-id pub-id-type="doi">10.1016/j.jksus.2020.101281</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Husain, A., Haque, S. M. J. &amp; Siddiqui, M. R. Identification of metabolic pathways involved in the biotransformation of eslicarbazepine acetate using UPLC-MS/MS, human microsomal enzymes and in silico studies. <italic toggle="yes">J. King Saud Univ. Sci.</italic><bold>33</bold>(2), 101281. 10.1016/j.jksus.2020.101281 (2021).</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haque</surname><given-names>SMJ</given-names></name></person-group><article-title>Box&#8211;Behnken experimental design for optimizing the HPLC method to determine hydrochlorothiazide in pharmaceutical formulations and biological fluid</article-title><source>J. Mol. Liq.</source><year>2022</year><volume>352</volume><fpage>118708</fpage><pub-id pub-id-type="doi">10.1016/j.molliq.2022.118708</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Haque, S. M. J. Box&#8211;Behnken experimental design for optimizing the HPLC method to determine hydrochlorothiazide in pharmaceutical formulations and biological fluid. <italic toggle="yes">J. Mol. Liq.</italic><bold>352</bold>, 118708. 10.1016/j.molliq.2022.118708 (2022).</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Siddiqui</surname><given-names>MR</given-names></name><name name-style="western"><surname>AlOthman</surname><given-names>ZA</given-names></name><name name-style="western"><surname>Rahman</surname><given-names>N</given-names></name></person-group><article-title>Analytical techniques in pharmaceutical analysis: A review</article-title><source>Arab. J. Chem.</source><year>2017</year><volume>10</volume><fpage>S1409</fpage><lpage>S1421</lpage><pub-id pub-id-type="doi">10.1016/j.arabjc.2013.04.016</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Siddiqui, M. R., AlOthman, Z. A. &amp; Rahman, N. Analytical techniques in pharmaceutical analysis: A review. <italic toggle="yes">Arab. J. Chem.</italic><bold>10</bold>, S1409&#8211;S1421. 10.1016/j.arabjc.2013.04.016 (2017).</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Sapingi</surname><given-names>MSM</given-names></name><etal/></person-group><source>The Treatment of Pharmaceutical Wastewater</source><year>2023</year><publisher-loc>The Netherlands</publisher-loc><publisher-name>Elsevier</publisher-name><fpage>149</fpage><lpage>177</lpage></element-citation><mixed-citation id="mc-CR7" publication-type="book">Sapingi, M. S. M. et al. <italic toggle="yes">The Treatment of Pharmaceutical Wastewater</italic> 149&#8211;177 (Elsevier, The Netherlands, 2023). 10.1016/B978-0-323-99160-5.00003-5.</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><mixed-citation publication-type="other">Chen, G. Z., Huang, X. Z., Xu, J. G., Zheng, Z., Wang, Z. <italic toggle="yes">The Methods of Fluorescence Analysis</italic>. Vol. 112 (Science Press, Beijing, 1990)</mixed-citation></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haque</surname><given-names>SMJ</given-names></name></person-group><article-title>Optimized Box&#8211;Behnken experimental design based response surface methodology and Youden&#8217;s robustness test to develop and validate methods to determine nateglinide using kinetic spectrophotometry</article-title><source>SAPAM B Spectrochim. Acta A Mol. Biomol. Spectrosc.</source><year>2022</year><volume>268</volume><fpage>120712</fpage><pub-id pub-id-type="doi">10.1016/j.saa.2021.120712</pub-id><pub-id pub-id-type="pmid">34896681</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Haque, S. M. J. Optimized Box&#8211;Behnken experimental design based response surface methodology and Youden&#8217;s robustness test to develop and validate methods to determine nateglinide using kinetic spectrophotometry. <italic toggle="yes">SAPAM B Spectrochim. Acta A Mol. Biomol. Spectrosc.</italic><bold>268</bold>, 120712. 10.1016/j.saa.2021.120712 (2022).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.saa.2021.120712</pub-id><pub-id pub-id-type="pmid">34896681</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jain</surname><given-names>B</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>R</given-names></name><name name-style="western"><surname>Verma</surname><given-names>N</given-names></name><etal/></person-group><article-title>Novel capsule phase microextraction-Gas chromatography-Mass spectrometry for analysis of pheniramine in a case of its fatal intoxication</article-title><source>Sustain. Chem. Pharm.</source><year>2023</year><volume>36</volume><fpage>101286</fpage><pub-id pub-id-type="doi">10.1016/j.scp.2023.101286</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Jain, B. et al. Novel capsule phase microextraction-Gas chromatography-Mass spectrometry for analysis of pheniramine in a case of its fatal intoxication. <italic toggle="yes">Sustain. Chem. Pharm.</italic><bold>36</bold>, 101286. 10.1016/j.scp.2023.101286 (2023).</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jain</surname><given-names>B</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>R</given-names></name><name name-style="western"><surname>Verma</surname><given-names>N</given-names></name><etal/></person-group><article-title>Multi-drug extraction using octanol supported rotating cellulose paper disc (RPD) device from complex biological matrices: Fabrication and application in forensic case work</article-title><source>Sustain. Chem. Pharm.</source><year>2024</year><volume>41</volume><fpage>101724</fpage><pub-id pub-id-type="doi">10.1016/j.scp.2024.101724</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Jain, B. et al. Multi-drug extraction using octanol supported rotating cellulose paper disc (RPD) device from complex biological matrices: Fabrication and application in forensic case work. <italic toggle="yes">Sustain. Chem. Pharm.</italic><bold>41</bold>, 101724. 10.1016/j.scp.2024.101724 (2024).</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haque</surname><given-names>SMJ</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>R</given-names></name><name name-style="western"><surname>Verma</surname><given-names>N</given-names></name><etal/></person-group><article-title>Greener spectrophotometric and HPLC investigation of CNS agent pregabalin: Taguchi model and box-behnken design for method parameters optimization</article-title><source>J. Mol. Struct.</source><year>2024</year><volume>1317</volume><fpage>139143</fpage><pub-id pub-id-type="doi">10.1016/j.molstruc.2024.139143</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Haque, S. M. J. et al. Greener spectrophotometric and HPLC investigation of CNS agent pregabalin: Taguchi model and box-behnken design for method parameters optimization. <italic toggle="yes">J. Mol. Struct.</italic><bold>1317</bold>, 139143. 10.1016/j.molstruc.2024.139143 (2024).</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>&#214;zdemir</surname><given-names>&#214;T</given-names></name></person-group><article-title>UV&#8211;vis, and NMR spectroscopic studies of antidiabetic molecule nateglinide</article-title><source>J. Spectrosc.</source><year>2018</year><volume>2018</volume><issue>1</issue><fpage>8573014</fpage><pub-id pub-id-type="doi">10.1155/2018/8573014</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">&#214;zdemir, &#214;. T. UV&#8211;vis, and NMR spectroscopic studies of antidiabetic molecule nateglinide. <italic toggle="yes">J. Spectrosc.</italic><bold>2018</bold>(1), 8573014. 10.1155/2018/8573014 (2018).</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abo Shabana</surname><given-names>R</given-names></name><name name-style="western"><surname>Zeid</surname><given-names>AM</given-names></name><name name-style="western"><surname>Abdelazim</surname><given-names>AH</given-names></name><etal/></person-group><article-title>Utility of synchronous fluorimetry for the concurrent quantitation of metoprolol and ivabradine</article-title><source>Spectrochim. Acta A Mol. Biomol. Spectrosc.</source><year>2022</year><volume>280</volume><fpage>121482</fpage><pub-id pub-id-type="doi">10.1016/j.saa.2022.121482</pub-id><pub-id pub-id-type="pmid">35717932</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Abo Shabana, R. et al. Utility of synchronous fluorimetry for the concurrent quantitation of metoprolol and ivabradine. <italic toggle="yes">Spectrochim. Acta A Mol. Biomol. Spectrosc.</italic><bold>280</bold>, 121482. 10.1016/j.saa.2022.121482 (2022).<pub-id pub-id-type="pmid">35717932</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.saa.2022.121482</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zeid</surname><given-names>AM</given-names></name><name name-style="western"><surname>El-Olemy</surname><given-names>A</given-names></name><name name-style="western"><surname>Abdelazim</surname><given-names>AH</given-names></name><etal/></person-group><article-title>First-order derivative synchronous spectrofluorimetric determination of two antihypertensive drugs, metolazone and valsartan, in pharmaceutical and biological matrices</article-title><source>Spectrochim. Acta A Mol. Biomol. Spectrosc.</source><year>2022</year><volume>267</volume><fpage>120591</fpage><pub-id pub-id-type="doi">10.1016/j.saa.2021.120591</pub-id><pub-id pub-id-type="pmid">34789407</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Zeid, A. M. et al. First-order derivative synchronous spectrofluorimetric determination of two antihypertensive drugs, metolazone and valsartan, in pharmaceutical and biological matrices. <italic toggle="yes">Spectrochim. Acta A Mol. Biomol. Spectrosc.</italic><bold>267</bold>, 120591. 10.1016/j.saa.2021.120591 (2022).<pub-id pub-id-type="pmid">34789407</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.saa.2021.120591</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramadan</surname><given-names>HS</given-names></name><name name-style="western"><surname>Roshdy</surname><given-names>A</given-names></name><name name-style="western"><surname>Barakat</surname><given-names>NT</given-names></name><etal/></person-group><article-title>First derivative synchronous spectrofluorimetric method for the simultaneous determination of tramadol and celecoxib in their dosage forms and human plasma</article-title><source>Luminescence</source><year>2024</year><volume>39</volume><issue>5</issue><fpage>e4774</fpage><pub-id pub-id-type="doi">10.1002/bio.4774</pub-id><pub-id pub-id-type="pmid">38757441</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Ramadan, H. S. et al. First derivative synchronous spectrofluorimetric method for the simultaneous determination of tramadol and celecoxib in their dosage forms and human plasma. <italic toggle="yes">Luminescence</italic><bold>39</bold>(5), e4774. 10.1002/bio.4774 (2024).<pub-id pub-id-type="pmid">38757441</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/bio.4774</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roshdy</surname><given-names>A</given-names></name><name name-style="western"><surname>Barakat</surname><given-names>NT</given-names></name><name name-style="western"><surname>El-Brashy</surname><given-names>AM</given-names></name><etal/></person-group><article-title>Fast concurrent determination of guaifenesin and pholcodine in formulations and spiked plasma using first derivative synchronous spectrofluorimetric approach</article-title><source>Luminescence</source><year>2024</year><volume>39</volume><issue>1</issue><fpage>e4660</fpage><pub-id pub-id-type="doi">10.1002/bio.4660</pub-id><pub-id pub-id-type="pmid">38286595</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Roshdy, A. et al. Fast concurrent determination of guaifenesin and pholcodine in formulations and spiked plasma using first derivative synchronous spectrofluorimetric approach. <italic toggle="yes">Luminescence</italic><bold>39</bold>(1), e4660. 10.1002/bio.4660 (2024).<pub-id pub-id-type="pmid">38286595</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/bio.4660</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barakat</surname><given-names>NT</given-names></name><name name-style="western"><surname>El-Brashy</surname><given-names>AM</given-names></name><name name-style="western"><surname>Fathy</surname><given-names>MEJ</given-names></name></person-group><article-title>Eco-friendly, sensitive and inventive first derivative synchronous spectrofluorimetric determination of ciprofloxacin and phenylephrine in their pure form, single and combined eye drops</article-title><source>BMC Chem.</source><year>2024</year><volume>18</volume><issue>1</issue><fpage>27</fpage><pub-id pub-id-type="doi">10.1186/s13065-024-01131-4</pub-id><pub-id pub-id-type="pmid">38317259</pub-id><pub-id pub-id-type="pmcid">PMC10845616</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Barakat, N. T., El-Brashy, A. M. &amp; Fathy, M. E. J. Eco-friendly, sensitive and inventive first derivative synchronous spectrofluorimetric determination of ciprofloxacin and phenylephrine in their pure form, single and combined eye drops. <italic toggle="yes">BMC Chem.</italic><bold>18</bold>(1), 27. 10.1186/s13065-024-01131-4 (2024).<pub-id pub-id-type="pmid">38317259</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13065-024-01131-4</pub-id><pub-id pub-id-type="pmcid">PMC10845616</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abdelwahab</surname><given-names>NS</given-names></name><name name-style="western"><surname>Abdelrahman</surname><given-names>MM</given-names></name></person-group><article-title>Simultaneous determination of methocarbamol and ibuprofen by first derivative synchronous fluorescence spectroscopic method in their binary mixture and spiked human plasma</article-title><source>J. Fluoresc.</source><year>2014</year><volume>24</volume><issue>1</issue><fpage>129</fpage><lpage>135</lpage><pub-id pub-id-type="doi">10.1007/s10895-013-1276-9</pub-id><pub-id pub-id-type="pmid">23912962</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Abdelwahab, N. S. &amp; Abdelrahman, M. M. Simultaneous determination of methocarbamol and ibuprofen by first derivative synchronous fluorescence spectroscopic method in their binary mixture and spiked human plasma. <italic toggle="yes">J. Fluoresc.</italic><bold>24</bold>(1), 129&#8211;135. 10.1007/s10895-013-1276-9 (2014).<pub-id pub-id-type="pmid">23912962</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10895-013-1276-9</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bakr</surname><given-names>NA</given-names></name><name name-style="western"><surname>Saad</surname><given-names>S</given-names></name><name name-style="western"><surname>Elshabrawy</surname><given-names>Y</given-names></name><name name-style="western"><surname>Eid</surname><given-names>M</given-names></name></person-group><article-title>First&#8208;derivative synchronous spectrofluorimetric method for estimation of losartan potassium and atorvastatin in their pure forms and in tablets</article-title><source>Luminescence</source><year>2020</year><volume>35</volume><issue>4</issue><fpage>561</fpage><lpage>571</lpage><pub-id pub-id-type="doi">10.1002/bio.3755</pub-id><pub-id pub-id-type="pmid">31957224</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Bakr, N. A., Saad, S., Elshabrawy, Y. &amp; Eid, M. First&#8208;derivative synchronous spectrofluorimetric method for estimation of losartan potassium and atorvastatin in their pure forms and in tablets. <italic toggle="yes">Luminescence</italic><bold>35</bold>(4), 561&#8211;571. 10.1002/bio.3755 (2020).<pub-id pub-id-type="pmid">31957224</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/bio.3755</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramzy</surname><given-names>S</given-names></name><name name-style="western"><surname>Abdelazim</surname><given-names>AH</given-names></name><name name-style="western"><surname>Hasan</surname><given-names>MA</given-names></name></person-group><article-title>Application of green first derivative synchronous spectrofluorometric method for quantitative analysis of fexofenadine hydrochloride and pseudoephedrine hydrochloride in pharmaceutical preparation and spiked human plasma</article-title><source>Biomed Chromatogr.</source><year>2022</year><volume>16</volume><issue>1</issue><fpage>62</fpage><pub-id pub-id-type="doi">10.1186/s13065-022-00855-5</pub-id><pub-id pub-id-type="pmcid">PMC9389777</pub-id><pub-id pub-id-type="pmid">35986381</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Ramzy, S., Abdelazim, A. H. &amp; Hasan, M. A. Application of green first derivative synchronous spectrofluorometric method for quantitative analysis of fexofenadine hydrochloride and pseudoephedrine hydrochloride in pharmaceutical preparation and spiked human plasma. <italic toggle="yes">Biomed Chromatogr.</italic><bold>16</bold>(1), 62. 10.1186/s13065-022-00855-5 (2022).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13065-022-00855-5</pub-id><pub-id pub-id-type="pmcid">PMC9389777</pub-id><pub-id pub-id-type="pmid">35986381</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elama</surname><given-names>HS</given-names></name><name name-style="western"><surname>Zeid</surname><given-names>AM</given-names></name><name name-style="western"><surname>Shalan</surname><given-names>SM</given-names></name><name name-style="western"><surname>El-Shabrawy</surname><given-names>Y</given-names></name><name name-style="western"><surname>Eid</surname><given-names>MI</given-names></name></person-group><article-title>Conventional and synchronous spectrofluorometric determination of the recently administered drugs for treatment of COVID-19 favipiravir and apixaban</article-title><source>Sci Rep.</source><year>2022</year><volume>12</volume><issue>1</issue><fpage>21520</fpage><pub-id pub-id-type="doi">10.1038/s41598-022-25917-5</pub-id><pub-id pub-id-type="pmid">36513795</pub-id><pub-id pub-id-type="pmcid">PMC9745689</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Elama, H. S., Zeid, A. M., Shalan, S. M., El-Shabrawy, Y. &amp; Eid, M. I. Conventional and synchronous spectrofluorometric determination of the recently administered drugs for treatment of COVID-19 favipiravir and apixaban. <italic toggle="yes">Sci Rep.</italic><bold>12</bold>(1), 21520. 10.1038/s41598-022-25917-5 (2022).<pub-id pub-id-type="pmid">36513795</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-022-25917-5</pub-id><pub-id pub-id-type="pmcid">PMC9745689</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gajula</surname><given-names>R</given-names></name><name name-style="western"><surname>Pilli</surname><given-names>NR</given-names></name><name name-style="western"><surname>Ravi</surname><given-names>VB</given-names></name><etal/></person-group><article-title>Simultaneous determination of atorvastatin and aspirin in human plasma by LC&#8211;MS/MS: Its pharmacokinetic application</article-title><source>Sci Pharm.</source><year>2012</year><volume>80</volume><issue>4</issue><fpage>923</fpage><pub-id pub-id-type="doi">10.3797/scipharm.1206-12</pub-id><pub-id pub-id-type="pmid">23264940</pub-id><pub-id pub-id-type="pmcid">PMC3528047</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Gajula, R. et al. Simultaneous determination of atorvastatin and aspirin in human plasma by LC&#8211;MS/MS: Its pharmacokinetic application. <italic toggle="yes">Sci Pharm.</italic><bold>80</bold>(4), 923. 10.3797/scipharm.1206-12 (2012).<pub-id pub-id-type="pmid">23264940</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3797/scipharm.1206-12</pub-id><pub-id pub-id-type="pmcid">PMC3528047</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Palur</surname><given-names>K</given-names></name><name name-style="western"><surname>Koganti</surname><given-names>B</given-names></name><name name-style="western"><surname>Archakam</surname><given-names>SC</given-names></name><etal/></person-group><article-title>Simultaneous estimation of atorvastatin and aspirin in bulk and capsule dosage form by chemometric assisted spectrophotometric methods</article-title><source>Sci. Pharm.</source><year>2016</year><volume>8</volume><issue>4</issue><fpage>424</fpage></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Palur, K. et al. Simultaneous estimation of atorvastatin and aspirin in bulk and capsule dosage form by chemometric assisted spectrophotometric methods. <italic toggle="yes">Sci. Pharm.</italic><bold>8</bold>(4), 424 (2016).</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sherikar</surname><given-names>O</given-names></name><name name-style="western"><surname>Mehta</surname><given-names>PJ</given-names></name></person-group><article-title>Comprehensive assessment of degradation behavior of aspirin and atorvastatin singly and in combination by using a validated RP-HPLC method</article-title><source>Sci. Pharm.</source><year>2012</year><volume>81</volume><issue>1</issue><fpage>195</fpage><pub-id pub-id-type="doi">10.3797/scipharm.1210-19</pub-id><pub-id pub-id-type="pmid">23641338</pub-id><pub-id pub-id-type="pmcid">PMC3617659</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Sherikar, O. &amp; Mehta, P. J. Comprehensive assessment of degradation behavior of aspirin and atorvastatin singly and in combination by using a validated RP-HPLC method. <italic toggle="yes">Sci. Pharm.</italic><bold>81</bold>(1), 195. 10.3797/scipharm.1210-19 (2012).<pub-id pub-id-type="pmid">23641338</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3797/scipharm.1210-19</pub-id><pub-id pub-id-type="pmcid">PMC3617659</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vora</surname><given-names>D</given-names></name><name name-style="western"><surname>Kadav</surname><given-names>A</given-names></name></person-group><article-title>Validated ultra HPLC method for the simultaneous determination of atorvastatin, aspirin, and their degradation products in capsules</article-title><source>J. Liq. Chromatogr. Relat. Technol.</source><year>2008</year><volume>31</volume><issue>18</issue><fpage>2821</fpage><lpage>2837</lpage><pub-id pub-id-type="doi">10.1080/10826070802388482</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Vora, D. &amp; Kadav, A. Validated ultra HPLC method for the simultaneous determination of atorvastatin, aspirin, and their degradation products in capsules. <italic toggle="yes">J. Liq. Chromatogr. Relat. Technol.</italic><bold>31</bold>(18), 2821&#8211;2837. 10.1080/10826070802388482 (2008).</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Azmi</surname><given-names>SNHJ</given-names></name><name name-style="western"><surname>Khan</surname><given-names>AA</given-names></name><name name-style="western"><surname>Ahmad</surname><given-names>A</given-names></name><etal/></person-group><article-title>Box&#8211;Behnken design based development of UV-reversed phase high performance liquid chromatographic method for determination of ascorbic acid in tablet formulation</article-title><source>MDPI</source><year>2022</year><volume>9</volume><issue>11</issue><fpage>361</fpage><pub-id pub-id-type="doi">10.3390/separations9110361</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Azmi, S. N. H. J. et al. Box&#8211;Behnken design based development of UV-reversed phase high performance liquid chromatographic method for determination of ascorbic acid in tablet formulation. <italic toggle="yes">MDPI</italic><bold>9</bold>(11), 361. 10.3390/separations9110361 (2022).</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haque</surname><given-names>SMJ</given-names></name><name name-style="western"><surname>Islam</surname><given-names>MT</given-names></name><name name-style="western"><surname>Alam</surname><given-names>MM</given-names></name><etal/></person-group><article-title>Application of Box&#8211;Behnken design combined response surface methodology to optimize HPLC and spectrophotometric techniques for quantifying febuxostat in pharmaceutical formulations and spiked wastewater samples</article-title><source>Microchem. J.</source><year>2023</year><volume>184</volume><fpage>108191</fpage><pub-id pub-id-type="doi">10.1016/j.microc.2022.108191</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Haque, S. M. J. et al. Application of Box&#8211;Behnken design combined response surface methodology to optimize HPLC and spectrophotometric techniques for quantifying febuxostat in pharmaceutical formulations and spiked wastewater samples. <italic toggle="yes">Microchem. J.</italic><bold>184</bold>, 108191. 10.1016/j.microc.2022.108191 (2023).</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patel</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Shah</surname><given-names>UAJ</given-names></name><name name-style="western"><surname>Patel</surname><given-names>CJ</given-names></name></person-group><article-title>Box&#8211;Behnken design-assisted optimization of RP-HPLC method for the estimation of evogliptin tartrate by analytical quality by design</article-title><source>Future J. Pharm Sci.</source><year>2023</year><volume>9</volume><issue>1</issue><fpage>57</fpage><pub-id pub-id-type="doi">10.1186/s43094-023-00509-w</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Patel, K. J., Shah, U. A. J. &amp; Patel, C. J. Box&#8211;Behnken design-assisted optimization of RP-HPLC method for the estimation of evogliptin tartrate by analytical quality by design. <italic toggle="yes">Future J. Pharm Sci.</italic><bold>9</bold>(1), 57. 10.1186/s43094-023-00509-w (2023).</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haque</surname><given-names>SMJ</given-names></name><name name-style="western"><surname>Islam</surname><given-names>MT</given-names></name><name name-style="western"><surname>Alam</surname><given-names>MM</given-names></name><etal/></person-group><article-title>The application of Box-Behnken-Design in the optimization of kinetic spectrophotometry and computational studies to determine and assessing eco-scale to green analytical chemistry for labetalol</article-title><source>J. Pharm. Innov.</source><year>2024</year><volume>19</volume><issue>3</issue><fpage>28</fpage><pub-id pub-id-type="doi">10.1007/s12247-024-09828-8</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Haque, S. M. J. et al. The application of Box-Behnken-Design in the optimization of kinetic spectrophotometry and computational studies to determine and assessing eco-scale to green analytical chemistry for labetalol. <italic toggle="yes">J. Pharm. Innov.</italic><bold>19</bold>(3), 28. 10.1007/s12247-024-09828-8 (2024).</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elkady</surname><given-names>EFJ</given-names></name><name name-style="western"><surname>Fouad</surname><given-names>MA</given-names></name><name name-style="western"><surname>Mozayad</surname><given-names>AN</given-names></name></person-group><article-title>Application of Box-Behnken experimental design and response surface methodology for selecting the optimum RP-HPLC conditions for the simultaneous determination of methocarbamol, indomethacin and betamethasone in their pharmaceutical dosage form</article-title><source>BMC Chem.</source><year>2022</year><volume>16</volume><issue>1</issue><fpage>114</fpage><pub-id pub-id-type="doi">10.1186/s13065-022-00908-9</pub-id><pub-id pub-id-type="pmid">36510282</pub-id><pub-id pub-id-type="pmcid">PMC9743662</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Elkady, E. F. J., Fouad, M. A. &amp; Mozayad, A. N. Application of Box-Behnken experimental design and response surface methodology for selecting the optimum RP-HPLC conditions for the simultaneous determination of methocarbamol, indomethacin and betamethasone in their pharmaceutical dosage form. <italic toggle="yes">BMC Chem.</italic><bold>16</bold>(1), 114. 10.1186/s13065-022-00908-9 (2022).<pub-id pub-id-type="pmid">36510282</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13065-022-00908-9</pub-id><pub-id pub-id-type="pmcid">PMC9743662</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Azmi</surname><given-names>SNHJ</given-names></name><name name-style="western"><surname>Khan</surname><given-names>AA</given-names></name><name name-style="western"><surname>Ahmad</surname><given-names>A</given-names></name><etal/></person-group><article-title>High performance liquid chromatographic method optimized by Box-Behnken design model to determine caffeine in pharmaceutical preparations and urine samples</article-title><source>J. Chromatogr B.</source><year>2024</year><volume>1234</volume><fpage>124035</fpage><pub-id pub-id-type="doi">10.1016/j.jchromb.2024.124035</pub-id><pub-id pub-id-type="pmid">38309045</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Azmi, S. N. H. J. et al. High performance liquid chromatographic method optimized by Box-Behnken design model to determine caffeine in pharmaceutical preparations and urine samples. <italic toggle="yes">J. Chromatogr B.</italic><bold>1234</bold>, 124035. 10.1016/j.jchromb.2024.124035 (2024).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jchromb.2024.124035</pub-id><pub-id pub-id-type="pmid">38309045</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haque</surname><given-names>SMJ</given-names></name><name name-style="western"><surname>Islam</surname><given-names>MT</given-names></name><name name-style="western"><surname>Alam</surname><given-names>MM</given-names></name></person-group><article-title>Validated kinetic spectrophotometric methods to optimize robustness study with Youden factorial combinations to determine repaglinide using response surface methodology via Box&#8211;Behnken design</article-title><source>Arab. J. Sci. Eng.</source><year>2023</year><volume>48</volume><issue>1</issue><fpage>129</fpage><lpage>144</lpage><pub-id pub-id-type="doi">10.1007/s13369-022-06782-w</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Haque, S. M. J., Islam, M. T. &amp; Alam, M. M. Validated kinetic spectrophotometric methods to optimize robustness study with Youden factorial combinations to determine repaglinide using response surface methodology via Box&#8211;Behnken design. <italic toggle="yes">Arab. J. Sci. Eng.</italic><bold>48</bold>(1), 129&#8211;144. 10.1007/s13369-022-06782-w (2023).</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al-Batty</surname><given-names>S</given-names></name><name name-style="western"><surname>Haque</surname><given-names>SM</given-names></name><name name-style="western"><surname>Rahman</surname><given-names>N</given-names></name><name name-style="western"><surname>Azmi</surname><given-names>SNH</given-names></name></person-group><article-title>Optimized box&#8211;Behnken design combined response surface methodology to determine calcium and iron contents using visible, atomic emission and atomic absorption spectrophotometry in vegetables and wastewater samples</article-title><source>J. AOAC In.</source><year>2023</year><volume>106</volume><issue>1</issue><fpage>99</fpage><lpage>111</lpage><pub-id pub-id-type="doi">10.1093/jaoacint/qsac106</pub-id><pub-id pub-id-type="pmid">36073907</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Al-Batty, S., Haque, S. M., Rahman, N. &amp; Azmi, S. N. H. Optimized box&#8211;Behnken design combined response surface methodology to determine calcium and iron contents using visible, atomic emission and atomic absorption spectrophotometry in vegetables and wastewater samples. <italic toggle="yes">J. AOAC In.</italic><bold>106</bold>(1), 99&#8211;111. 10.1093/jaoacint/qsac106 (2023).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jaoacint/qsac106</pub-id><pub-id pub-id-type="pmid">36073907</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mostafa</surname><given-names>EA</given-names></name><name name-style="western"><surname>El-Ashrey</surname><given-names>MK</given-names></name><name name-style="western"><surname>Mahmoud</surname><given-names>ST</given-names></name></person-group><article-title>An innovative combination of Box-Behnken design and ecofriendly approaches for the simultaneous determination of aspirin, clopidogrel, atorvastatin and rosuvastatin in their fixed-dose combination tablets</article-title><source>BMC Chem.</source><year>2023</year><volume>17</volume><issue>1</issue><fpage>164</fpage><pub-id pub-id-type="doi">10.1186/s13065-023-01079-x</pub-id><pub-id pub-id-type="pmid">38001500</pub-id><pub-id pub-id-type="pmcid">PMC10668404</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Mostafa, E. A., El-Ashrey, M. K. &amp; Mahmoud, S. T. An innovative combination of Box-Behnken design and ecofriendly approaches for the simultaneous determination of aspirin, clopidogrel, atorvastatin and rosuvastatin in their fixed-dose combination tablets. <italic toggle="yes">BMC Chem.</italic><bold>17</bold>(1), 164. 10.1186/s13065-023-01079-x (2023).<pub-id pub-id-type="pmid">38001500</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13065-023-01079-x</pub-id><pub-id pub-id-type="pmcid">PMC10668404</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haque</surname><given-names>SM</given-names></name><name name-style="western"><surname>Kabir</surname><given-names>A</given-names></name><name name-style="western"><surname>Rahman</surname><given-names>N</given-names></name><name name-style="western"><surname>Azmi</surname><given-names>SNH</given-names></name></person-group><article-title>Response surface methodology combined Box-Behnken design optimized green kinetic spectrophotometric and HPLC methods to quantify angiotensin receptor blocker valsartan in pharmaceutical formulations</article-title><source>Spectrochim Acta A Mol Biomol Spectrosc.</source><year>2023</year><volume>298</volume><fpage>122805</fpage><pub-id pub-id-type="doi">10.1016/j.saa.2023.122805</pub-id><pub-id pub-id-type="pmid">37156177</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Haque, S. M., Kabir, A., Rahman, N. &amp; Azmi, S. N. H. Response surface methodology combined Box-Behnken design optimized green kinetic spectrophotometric and HPLC methods to quantify angiotensin receptor blocker valsartan in pharmaceutical formulations. <italic toggle="yes">Spectrochim Acta A Mol Biomol Spectrosc.</italic><bold>298</bold>, 122805. 10.1016/j.saa.2023.122805 (2023).<pub-id pub-id-type="pmid">37156177</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.saa.2023.122805</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mansour</surname><given-names>FR</given-names></name><name name-style="western"><surname>Omer</surname><given-names>KM</given-names></name><name name-style="western"><surname>P&#322;otka-Wasylka</surname><given-names>J</given-names></name></person-group><article-title>A total scoring system and software for complex modified GAPI (ComplexMoGAPI) application in the assessment of method greenness</article-title><source>Green Anal. Chem.</source><year>2024</year><volume>10</volume><fpage>100126</fpage><pub-id pub-id-type="doi">10.1016/j.greeac.2024.100126</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Mansour, F. R., Omer, K. M. &amp; P&#322;otka-Wasylka, J. A total scoring system and software for complex modified GAPI (ComplexMoGAPI) application in the assessment of method greenness. <italic toggle="yes">Green Anal. Chem.</italic><bold>10</bold>, 100126. 10.1016/j.greeac.2024.100126 (2024).</mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gamal</surname><given-names>M</given-names></name><name name-style="western"><surname>Naguib</surname><given-names>IA</given-names></name><name name-style="western"><surname>Panda</surname><given-names>DS</given-names></name><etal/></person-group><article-title>Comparative study of four greenness assessment tools for selection of greenest analytical method for assay of hyoscine N-butyl bromide</article-title><source>Anal. Methods.</source><year>2021</year><volume>13</volume><issue>3</issue><fpage>369</fpage><lpage>380</lpage><pub-id pub-id-type="doi">10.1039/d0ay02169e</pub-id><pub-id pub-id-type="pmid">33404016</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Gamal, M. et al. Comparative study of four greenness assessment tools for selection of greenest analytical method for assay of hyoscine N-butyl bromide. <italic toggle="yes">Anal. Methods.</italic><bold>13</bold>(3), 369&#8211;380. 10.1039/d0ay02169e (2021).<pub-id pub-id-type="pmid">33404016</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1039/d0ay02169e</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Keith</surname><given-names>LH</given-names></name><name name-style="western"><surname>Gron</surname><given-names>LU</given-names></name><name name-style="western"><surname>Young</surname><given-names>JL</given-names></name></person-group><article-title>Green analytical methodologies</article-title><source>Chem. Rev.</source><year>2007</year><volume>107</volume><issue>6</issue><fpage>2695</fpage><lpage>2708</lpage><pub-id pub-id-type="doi">10.1021/cr068359e</pub-id><pub-id pub-id-type="pmid">17521200</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Keith, L. H., Gron, L. U. &amp; Young, J. L. Green analytical methodologies. <italic toggle="yes">Chem. Rev.</italic><bold>107</bold>(6), 2695&#8211;2708 (2007).<pub-id pub-id-type="pmid">17521200</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/cr068359e</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>P&#322;otka-Wasylka</surname><given-names>J</given-names></name><name name-style="western"><surname>Wojnowski</surname><given-names>W</given-names></name></person-group><article-title>Complementary green analytical procedure index (ComplexGAPI) and software</article-title><source>Green Chem.</source><year>2021</year><volume>23</volume><issue>21</issue><fpage>8657</fpage><lpage>8665</lpage><pub-id pub-id-type="doi">10.1039/D1GC02318G</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">P&#322;otka-Wasylka, J. &amp; Wojnowski, W. Complementary green analytical procedure index (ComplexGAPI) and software. <italic toggle="yes">Green Chem.</italic><bold>23</bold>(21), 8657&#8211;8665 (2021).</mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sinzervinch</surname><given-names>A</given-names></name><name name-style="western"><surname>Torres</surname><given-names>IMS</given-names></name><name name-style="western"><surname>Kogawa</surname><given-names>AC</given-names></name></person-group><article-title>Tools to evaluate the eco-efficiency of analytical methods in the context of green and white analytical chemistry: A review</article-title><source>Curr. Pharm Des.</source><year>2023</year><volume>29</volume><issue>31</issue><fpage>2442</fpage><lpage>2449</lpage><pub-id pub-id-type="doi">10.2174/0113816128266396231017072043</pub-id><pub-id pub-id-type="pmid">37877508</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Sinzervinch, A., Torres, I. M. S. &amp; Kogawa, A. C. Tools to evaluate the eco-efficiency of analytical methods in the context of green and white analytical chemistry: A review. <italic toggle="yes">Curr. Pharm Des.</italic><bold>29</bold>(31), 2442&#8211;2449. 10.2174/0113816128266396231017072043 (2023).<pub-id pub-id-type="pmid">37877508</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/0113816128266396231017072043</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haque</surname><given-names>SMJ</given-names></name></person-group><article-title>Optimized Box&#8211;Behnken experimental design based response surface methodology and Youden&#8217;s robustness test to develop and validate methods to determine nateglinide using kinetic spectrophotometry</article-title><source>SAPAM, Spectrosc. B Spectrochim. Acta A Mol. Biomol. Spectrosc.</source><year>2022</year><volume>268</volume><fpage>120712</fpage><pub-id pub-id-type="doi">10.1016/j.saa.2021.120712</pub-id><pub-id pub-id-type="pmid">34896681</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Haque, S. M. J. Optimized Box&#8211;Behnken experimental design based response surface methodology and Youden&#8217;s robustness test to develop and validate methods to determine nateglinide using kinetic spectrophotometry. <italic toggle="yes">SAPAM, Spectrosc. B Spectrochim. Acta A Mol. Biomol. Spectrosc.</italic><bold>268</bold>, 120712. 10.1016/j.saa.2021.120712 (2022).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.saa.2021.120712</pub-id><pub-id pub-id-type="pmid">34896681</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nassef</surname><given-names>HMJ</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>HA</given-names></name><name name-style="western"><surname>Bashal</surname><given-names>AH</given-names></name><etal/></person-group><article-title>A novel Six Sigma approach and eco-friendly RP-HPLC technique for determination of pimavanserin and its degraded products: Application of Box&#8211;Behnken design</article-title><source>J. Rev. Anal. Chem.</source><year>2024</year><volume>43</volume><issue>1</issue><fpage>20230073</fpage><pub-id pub-id-type="doi">10.1515/revac-2023-0073</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Nassef, H. M. J. et al. A novel Six Sigma approach and eco-friendly RP-HPLC technique for determination of pimavanserin and its degraded products: Application of Box&#8211;Behnken design. <italic toggle="yes">J. Rev. Anal. Chem.</italic><bold>43</bold>(1), 20230073. 10.1515/revac-2023-0073 (2024).</mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haque</surname><given-names>SMJ</given-names></name><name name-style="western"><surname>Umar</surname><given-names>Y</given-names></name><name name-style="western"><surname>Abu-Judeh</surname><given-names>A</given-names></name><etal/></person-group><article-title>Greener high-performance liquid chromatography&#8212;supported with computational studies to determine empagliflozin: box&#8211;behnken design and Taguchi model for optimization</article-title><source>Arab. J. Sci. Eng.</source><year>2024</year><volume>49</volume><issue>7</issue><fpage>9667</fpage><lpage>9689</lpage><pub-id pub-id-type="doi">10.1007/s13369-024-09023-4</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">Haque, S. M. J. et al. Greener high-performance liquid chromatography&#8212;supported with computational studies to determine empagliflozin: box&#8211;behnken design and Taguchi model for optimization. <italic toggle="yes">Arab. J. Sci. Eng.</italic><bold>49</bold>(7), 9667&#8211;9689. 10.1007/s13369-024-09023-4 (2024).</mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haque</surname><given-names>SMJ</given-names></name></person-group><article-title>Application of combined Box&#8211;Behnken design with response surface methodology and desirability function in optimizing pectin extraction from fruit peels</article-title><source>J. Sci. Food Agric.</source><year>2024</year><volume>104</volume><issue>1</issue><fpage>149</fpage><lpage>173</lpage><pub-id pub-id-type="doi">10.1002/jsfa.12925</pub-id><pub-id pub-id-type="pmid">37574926</pub-id></element-citation><mixed-citation id="mc-CR45" publication-type="journal">Haque, S. M. J. Application of combined Box&#8211;Behnken design with response surface methodology and desirability function in optimizing pectin extraction from fruit peels. <italic toggle="yes">J. Sci. Food Agric.</italic><bold>104</bold>(1), 149&#8211;173. 10.1002/jsfa.12925 (2024).<pub-id pub-id-type="pmid">37574926</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jsfa.12925</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alshehri</surname><given-names>SAJ</given-names></name><name name-style="western"><surname>Wahab</surname><given-names>S</given-names></name><name name-style="western"><surname>Khalid</surname><given-names>M</given-names></name><etal/></person-group><article-title>Optimization of chromatographic conditions via Box-Behnken design in RP-HPLC-PDA method development for the estimation of folic acid and methotrexate in bulk and tablets</article-title><source>Heliyon</source><year>2023</year><pub-id pub-id-type="doi">10.1016/j.heliyon.2023.e20282</pub-id><pub-id pub-id-type="pmid">37771532</pub-id><pub-id pub-id-type="pmcid">PMC10522955</pub-id></element-citation><mixed-citation id="mc-CR46" publication-type="journal">Alshehri, S. A. J. et al. Optimization of chromatographic conditions via Box-Behnken design in RP-HPLC-PDA method development for the estimation of folic acid and methotrexate in bulk and tablets. <italic toggle="yes">Heliyon</italic>10.1016/j.heliyon.2023.e20282 (2023).<pub-id pub-id-type="pmid">37771532</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.heliyon.2023.e20282</pub-id><pub-id pub-id-type="pmcid">PMC10522955</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mattrey</surname><given-names>FT</given-names></name><name name-style="western"><surname>Makarov</surname><given-names>AA</given-names></name><name name-style="western"><surname>Regalado</surname><given-names>EL</given-names></name><etal/></person-group><article-title>Current challenges and future prospects in chromatographic method development for pharmaceutical research</article-title><source>Trac - Trends In Anal. Chem.</source><year>2017</year><volume>95</volume><fpage>36</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1016/j.trac.2017.07.021</pub-id></element-citation><mixed-citation id="mc-CR47" publication-type="journal">Mattrey, F. T. et al. Current challenges and future prospects in chromatographic method development for pharmaceutical research. <italic toggle="yes">Trac - Trends In Anal. Chem.</italic><bold>95</bold>, 36&#8211;46. 10.1016/j.trac.2017.07.021 (2017).</mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rahman</surname><given-names>N</given-names></name><name name-style="western"><surname>Rahman</surname><given-names>H</given-names></name><name name-style="western"><surname>Haque</surname><given-names>SMJ</given-names></name></person-group><article-title>Kinetic spectrophotometric method for the determination of perindopril erbumine in pure and commercial dosage forms</article-title><source>Arab. J. Chem.</source><year>2017</year><volume>10</volume><fpage>S831</fpage><lpage>S838</lpage><pub-id pub-id-type="doi">10.1016/j.arabjc.2012.12.017</pub-id></element-citation><mixed-citation id="mc-CR48" publication-type="journal">Rahman, N., Rahman, H. &amp; Haque, S. M. J. Kinetic spectrophotometric method for the determination of perindopril erbumine in pure and commercial dosage forms. <italic toggle="yes">Arab. J. Chem.</italic><bold>10</bold>, S831&#8211;S838. 10.1016/j.arabjc.2012.12.017 (2017).</mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abdel-Raoof</surname><given-names>AM</given-names></name><name name-style="western"><surname>Hasan</surname><given-names>MA</given-names></name><name name-style="western"><surname>Madkour</surname><given-names>AW</given-names></name><name name-style="western"><surname>Abdel-Fattah</surname><given-names>A</given-names></name><name name-style="western"><surname>Eissa</surname><given-names>MS</given-names></name></person-group><article-title>Simultaneous determination of citalopram and tadalafil by the second derivative synchronous fluorescence method in biological fluids; application of Box&#8211;Behnken optimization design</article-title><source>J. Luminesc.</source><year>2021</year><volume>36</volume><issue>1</issue><fpage>57</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1002/bio.3913</pub-id><pub-id pub-id-type="pmid">32678940</pub-id></element-citation><mixed-citation id="mc-CR49" publication-type="journal">Abdel-Raoof, A. M., Hasan, M. A., Madkour, A. W., Abdel-Fattah, A. &amp; Eissa, M. S. Simultaneous determination of citalopram and tadalafil by the second derivative synchronous fluorescence method in biological fluids; application of Box&#8211;Behnken optimization design. <italic toggle="yes">J. Luminesc.</italic><bold>36</bold>(1), 57&#8211;65. 10.1002/bio.3913 (2021).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/bio.3913</pub-id><pub-id pub-id-type="pmid">32678940</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rahman</surname><given-names>N</given-names></name><name name-style="western"><surname>Sameen</surname><given-names>S</given-names></name><name name-style="western"><surname>Kashif</surname><given-names>M</given-names></name></person-group><article-title>Application of Box-Behnken design and desirability function in the optimization of spectrophotometric method for the quantification of WADA banned drug: Acetazolamide</article-title><source>J. Mol. Liq.</source><year>2019</year><volume>274</volume><fpage>270</fpage><lpage>277</lpage><pub-id pub-id-type="doi">10.1016/j.molliq.2018.10.120</pub-id></element-citation><mixed-citation id="mc-CR50" publication-type="journal">Rahman, N., Sameen, S. &amp; Kashif, M. Application of Box-Behnken design and desirability function in the optimization of spectrophotometric method for the quantification of WADA banned drug: Acetazolamide. <italic toggle="yes">J. Mol. Liq.</italic><bold>274</bold>, 270&#8211;277. 10.1016/j.molliq.2018.10.120 (2019).</mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Youssef</surname><given-names>RM</given-names></name><name name-style="western"><surname>El-Nahass</surname><given-names>SA</given-names></name><name name-style="western"><surname>Soliman</surname><given-names>SA</given-names></name><etal/></person-group><article-title>Development of hybrid spectrofluorimetric method for simultaneous determination of Valsartan and Sacubitril in LCZ696 tablets</article-title><source>Spectrochim. Acta A Mol. Biomol. Spectrosc.</source><year>2021</year><volume>256</volume><fpage>119748</fpage><pub-id pub-id-type="doi">10.1016/j.saa.2021.119748</pub-id><pub-id pub-id-type="pmid">33845336</pub-id></element-citation><mixed-citation id="mc-CR51" publication-type="journal">Youssef, R. M. et al. Development of hybrid spectrofluorimetric method for simultaneous determination of Valsartan and Sacubitril in LCZ696 tablets. <italic toggle="yes">Spectrochim. Acta A Mol. Biomol. Spectrosc.</italic><bold>256</bold>, 119748. 10.1016/j.saa.2021.119748 (2021).<pub-id pub-id-type="pmid">33845336</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.saa.2021.119748</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ert&#252;rk</surname><given-names>S</given-names></name><name name-style="western"><surname>Akta&#351;</surname><given-names>ES</given-names></name><name name-style="western"><surname>Ersoy</surname><given-names>L</given-names></name><name name-style="western"><surname>F&#305;&#231;&#305;c&#305;o&#287;lu</surname><given-names>S</given-names></name></person-group><article-title>An HPLC method for the determination of atorvastatin and its impurities in bulk drug and tablets</article-title><source>J. Pharm. Biomed. Anal.</source><year>2003</year><volume>33</volume><issue>5</issue><fpage>1017</fpage><lpage>1023</lpage><pub-id pub-id-type="doi">10.1016/S0731-7085(03)00408-4</pub-id><pub-id pub-id-type="pmid">14656592</pub-id></element-citation><mixed-citation id="mc-CR52" publication-type="journal">Ert&#252;rk, S., Akta&#351;, E. S., Ersoy, L. &amp; F&#305;&#231;&#305;c&#305;o&#287;lu, S. An HPLC method for the determination of atorvastatin and its impurities in bulk drug and tablets. <italic toggle="yes">J. Pharm. Biomed. Anal.</italic><bold>33</bold>(5), 1017&#8211;1023. 10.1016/S0731-7085(03)00408-4 (2003).<pub-id pub-id-type="pmid">14656592</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0731-7085(03)00408-4</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kowalska</surname><given-names>M</given-names></name><name name-style="western"><surname>Wo&#378;niak</surname><given-names>M</given-names></name><name name-style="western"><surname>Kijek</surname><given-names>M</given-names></name><name name-style="western"><surname>Mitrosz</surname><given-names>P</given-names></name><name name-style="western"><surname>Szakiel</surname><given-names>J</given-names></name><name name-style="western"><surname>Turek</surname><given-names>PJSR</given-names></name></person-group><article-title>Management of validation of HPLC method for determination of acetylsalicylic acid impurities in a new pharmaceutical product</article-title><source>J. Sci. Rep.</source><year>2022</year><volume>12</volume><issue>1</issue><fpage>1</fpage><pub-id pub-id-type="doi">10.1038/s41598-021-99269-x</pub-id><pub-id pub-id-type="pmcid">PMC8738756</pub-id><pub-id pub-id-type="pmid">34992227</pub-id></element-citation><mixed-citation id="mc-CR53" publication-type="journal">Kowalska, M. et al. Management of validation of HPLC method for determination of acetylsalicylic acid impurities in a new pharmaceutical product. <italic toggle="yes">J. Sci. Rep.</italic><bold>12</bold>(1), 1. 10.1038/s41598-021-99269-x (2022).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-021-99269-x</pub-id><pub-id pub-id-type="pmcid">PMC8738756</pub-id><pub-id pub-id-type="pmid">34992227</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Darwish</surname><given-names>IA</given-names></name><name name-style="western"><surname>Darwish</surname><given-names>HW</given-names></name><name name-style="western"><surname>Alzoman</surname><given-names>NZ</given-names></name><name name-style="western"><surname>Ali</surname><given-names>AM</given-names></name></person-group><article-title>Assay for direct determination of statins in bulk forms and pharmaceutical formulations: a green eco-friendly and high-throughput analytical approach</article-title><source>Molecules</source><year>2023</year><volume>28</volume><issue>6</issue><fpage>2808</fpage><pub-id pub-id-type="doi">10.3390/molecules28062808</pub-id><pub-id pub-id-type="pmid">36985779</pub-id><pub-id pub-id-type="pmcid">PMC10051747</pub-id></element-citation><mixed-citation id="mc-CR54" publication-type="journal">Darwish, I. A., Darwish, H. W., Alzoman, N. Z. &amp; Ali, A. M. Assay for direct determination of statins in bulk forms and pharmaceutical formulations: a green eco-friendly and high-throughput analytical approach. <italic toggle="yes">Molecules</italic><bold>28</bold>(6), 2808. 10.3390/molecules28062808 (2023).<pub-id pub-id-type="pmid">36985779</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/molecules28062808</pub-id><pub-id pub-id-type="pmcid">PMC10051747</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>El-Din</surname><given-names>MMS</given-names></name><name name-style="western"><surname>Salama</surname><given-names>FM</given-names></name><name name-style="western"><surname>Nassar</surname><given-names>MW</given-names></name><name name-style="western"><surname>Attia</surname><given-names>KA</given-names></name><name name-style="western"><surname>Kaddah</surname><given-names>MM</given-names></name></person-group><article-title>Validated spectrofluorimetric method for the determination of atorvastatin in pharmaceutical preparations</article-title><source>J Pharm Anal.</source><year>2012</year><volume>2</volume><issue>3</issue><fpage>200</fpage><lpage>205</lpage><pub-id pub-id-type="doi">10.1016/j.jpha.2012.01.005</pub-id><pub-id pub-id-type="pmid">29403743</pub-id><pub-id pub-id-type="pmcid">PMC5760905</pub-id></element-citation><mixed-citation id="mc-CR55" publication-type="journal">El-Din, M. M. S., Salama, F. M., Nassar, M. W., Attia, K. A. &amp; Kaddah, M. M. Validated spectrofluorimetric method for the determination of atorvastatin in pharmaceutical preparations. <italic toggle="yes">J Pharm Anal.</italic><bold>2</bold>(3), 200&#8211;205. 10.1016/j.jpha.2012.01.005 (2012).<pub-id pub-id-type="pmid">29403743</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jpha.2012.01.005</pub-id><pub-id pub-id-type="pmcid">PMC5760905</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karim</surname><given-names>MM</given-names></name><name name-style="western"><surname>Jeon</surname><given-names>CW</given-names></name><name name-style="western"><surname>Lee</surname><given-names>HS</given-names></name><name name-style="western"><surname>Alam</surname><given-names>SM</given-names></name><name name-style="western"><surname>Lee</surname><given-names>SH</given-names></name><name name-style="western"><surname>Choi</surname><given-names>JH</given-names></name><etal/></person-group><article-title>Simultaneous determination of acetylsalicylic acid and caffeine in pharmaceutical formulation by first derivative synchronous fluorimetric method</article-title><source>J. Fluoresc.</source><year>2006</year><volume>16</volume><fpage>713</fpage><lpage>721</lpage><pub-id pub-id-type="doi">10.1007/s10895-006-0115-7</pub-id><pub-id pub-id-type="pmid">16952012</pub-id></element-citation><mixed-citation id="mc-CR56" publication-type="journal">Karim, M. M. et al. Simultaneous determination of acetylsalicylic acid and caffeine in pharmaceutical formulation by first derivative synchronous fluorimetric method. <italic toggle="yes">J. Fluoresc.</italic><bold>16</bold>, 713&#8211;721. 10.1007/s10895-006-0115-7 (2006).<pub-id pub-id-type="pmid">16952012</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10895-006-0115-7</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Branch</surname><given-names>SK</given-names></name></person-group><article-title>Guidelines from the international conference on harmonisation (ICH)</article-title><source>J. Pharm. Biomed. Anal.</source><year>2005</year><volume>38</volume><issue>5</issue><fpage>798</fpage><lpage>805</lpage><pub-id pub-id-type="doi">10.1016/j.jpba.2005.02.037</pub-id><pub-id pub-id-type="pmid">16076542</pub-id></element-citation><mixed-citation id="mc-CR57" publication-type="journal">Branch, S. K. Guidelines from the international conference on harmonisation (ICH). <italic toggle="yes">J. Pharm. Biomed. Anal.</italic><bold>38</bold>(5), 798&#8211;805 (2005).<pub-id pub-id-type="pmid">16076542</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jpba.2005.02.037</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article></pmc-articleset>